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Parkinson`s disease (PD) is an age-related neurodegenerative disorder with progressive 
disability. Its incidence is expected to increase substantially owing to ageing of world 
population. Better general healthcare, and better understanding of complications and 
clinical management of PD is likely to increase in the future the prevalence of PD patients 
in very advanced stages of disease, when disability is most severe. These very advanced 
patients will represent an important burden for families and the healthcare and social 
systems, and a new challenge for healthcare personnel. Nevertheless, the clinical 
characteristics of these late-stage PD (LS-PD) patients have been only partially described 
in the pre-levodopa or post-levodopa era. Since knowledge of the health needs of these 
patients is crucial to plan effective health resources that cover patients and caregivers 
needs, we aimed to study the clinical features and handicap of LS-PD patients attending 
two tertiary centres, selected on the basis of motor disability. We also aimed to study 
whether the handicap of LS-PD patients differs from that of classical advanced stage PD 
patients, i.e., patients manifesting disabling levodopa-induced motor complications, and, 
if so, whether that modifies the way we conceive today the natural history of PD. Finally, 
we reviewed the pharmacological and non-pharmacological interventions available to 
treat the non-motor symptoms of LS-PD, using a systematic approach.    
Participants were LS-PD (stage 4 or 5 of Hoehn & Yahr scale in on state) and advanced 
stage PD patients (patients with disabling levodopa-induced motor complications selected 
to deep brain stimulation), and their informal caregivers. Cross-sectional data were 
obtained using comprehensive clinical assessment. Handicap was assessed using the 
London Handicap Scale (LHS). Descriptive and regression analysis was performed. To 
review the treatment available for non-motor symptoms in LS-PD, we extracted the 
controlled clinical trials for PD dementia, psychosis, falls, bone fractures, joint and skeletal 
deformities, pain, orthostatic hypotension, gastrointestinal abnormalities and urological 
dysfunction; we chose these symptoms because they were considered as the most 
disabling for LS-PD patients, based on our results and published data. 
50 LS-PD patients (mean age 74.1 years and mean disease duration 17.9 years) were 
studied. Severe akinetic symmetric parkinsonism was present in most, with negligible 
rigidity and tremor, and most patients were wheelchair-bound. Postural instability and 
freezing of gait, causing frequent falls and fractures, and prominent dysarthria and 
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dysphagia dominated the motor syndrome. Levodopa, used as monotherapy in one-third 
of the cases, remained partially effective in most patients but with limited clinical 
relevance. Dosage of antiparkinsonian drugs was probably influenced by the frequent 
occurrence of neuropsychiatric symptoms. Motor fluctuations and dyskinesias were 
frequent but not disabling. All had neuropsychiatric and dysautonomic symptoms, namely 
dementia and visual hallucinations in half and depression in two-thirds of the patients. 
Lack of tremor and absence of depression were independently associated with dementia. 
Greatest impact on perceived health status was due to motor and non-motor levodopa-
resistant symptoms. The LHS was easy to use in these patients and their caregivers. 
Handicap was severe and determined by dementia, behavioural complaints and the 
severity of non-dopaminergic motor features. Most affected domain of handicap was 
Orientation. Co-morbidities and past medical conditions were frequent. Patients visited 
doctors infrequently and made low use of health resources, while unpaid caregivers 
reported a high burden which correlated with patients’ handicap. The LHS was also easily 
completed by 100 advanced stage PD patients (mean age 61 years and mean disease 
duration 12.2 years) and their carers. Handicap was moderate-to-severe, although less 
than that of LS-PD patients. In contrast to the latter, Physical Independence and Social 
Integration were the most affected domains, and the determinants of handicap were 
disability in ADL and dyskinesias.  
The clinical features, severity and determinants of handicap of PD patients in late-stage 
differ from those in advanced stage, although they are nowadays classified under the 
generic category of advanced stage patients. LS-PD patients are severely handicapped 
from axial motor and non-motor symptoms unresponsive to levodopa, and they are very 
dependent on caregivers. Data suggest that LS-PD is a very distinct sub-group of advanced 
stage PD, and we propose an operational definition for LS-PD that anchors on (lack) of 
functionality regardless the cause is motor or non-motor symptomatology, using the 
Schwab and England scale in on. Unfortunately, few controlled clinical trials are available 
to treat most non-motor symptoms that disable LS-PD patients. Best evidence exists for 
the treatment of dementia, psychosis, osteoporosis and prevention of fractures, and 
sialorrhea.  
  Abstract 
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The present study provides cross-sectional evidence that LS-PD is a distinct sub-group of 
advanced stage PD, and that LS-PD patients manifest a clinical picture dominated by a 
severe akinetic symmetric non-dopaminergic motor phenotype and by severe non-motor 
features, which are overall poorly responsive to levodopa. LHS is easily completed by PD 
patients and handicap can be further explored as a patient-centred outcome in PD. 
Caregivers have a high burden that is correlated with patients’ handicap. In face of an 
expected increase in the prevalence of LS-PD and lack of efficacious therapies for most 
disabling symptoms, future research and allocation of funds should focus on non-
levodopa responsive aspects of the disease and the needs of caregivers. 
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A doença de Parkinson (DP) é uma doença neurodegenerativa cuja incidência aumenta 
com a idade, e prevê-se que a sua prevalência aumente no futuro devido ao 
envelhecimento da população mundial. O aumento da esperança de vida, as melhores 
condições gerais de saúde e o melhor entendimento e tratamento actual da DP serão 
também responsáveis pelo fututo aumento do número de doentes com DP que se 
encontram nas fases mais avançadas da doença. Os doentes na fase tardia da DP (LS-PD) 
estão muito incapacitados, sobretudo pela ocorrência de sintomas motores e não 
motores que respondem mal à levodopa. Esta população de doentes será uma sobrecarga 
muito grande para os seus cuidadores, para o sistema de saúde e da segurança social, e 
ainda um desafio para os técnicos de saúde que estão pouco habituados e habilitados a 
manejar estes doentes. Apesar do acima exposto, as características destes doentes são 
mal conhecidas e pouco reportadas na literatura das eras pré- e pós-levodopa. No 
entanto, o planeamento dos recursos de  saúde e sociais a alocar a estes doentes e seus 
cuidadores exige um conhecimento preciso e substancial das suas características clínicas, 
da causa da sua incapacidade, da forma como são tratados hoje em dia e usam o sistema 
de saúde, e de quais as actuais intervenções terapêuticas eficazes nesta população de 
doentes. 
Foi nosso propósito estudar as características clínicas e a incapacidade (“handicap”) de 
uma população de doentes LS-PD consultados em 2 clínicas de movimento de hospitais 
terciários, recrutados com base na sua incapacidade motora. Adicionalmente, tivemos 
por objectivo averiguar se a intensidade e causa da incapacidade destes doentes difere 
daquela dos doentes classicamente referidos como estando em estádio avançado, isto é, 
doentes com complicações motoras incapacitantes induzidas pela levodopa, e, a ser 
verdade, se tal mudaria a forma como entendemos hoje a história natural da DP. Por 
último, revimos de forma sistematizada qual a eficácia e segurança das intervenções 
farmacológicas e não-farmacológicas para tratamentos dos sintomas não motores da LS-
PD.       
Participaram neste estudo doentes LS-PD (doentes em estádio 4 ou 5 de Hoehn e Yahr em 
on), doentes em estádio avançado (doentes com complicações motoras incapacitantes 
induzidas pela levodopa e seleccionados para estimulação cerebral profunda), e os seus 
cuidadores. Procedeu-se a uma colheita transversal dos dados, usando um questionário 
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semi-estruturado, escalas apropriadas, o exame objectivo e recorrendo aos processos 
clínicos em caso de dúvida ou omissão de dados. O handicap foi medido usando a London 
Handicap Scale (LHS). Fez-se uma análise descritiva dos dados e modelos de regressão. 
Para a revisão das intervenções terapêuticas, procedeu-se a uma extracção dos ensaios 
clínicos controlados nas seguintes indicações: demência associada à DP, psicose, quedas, 
fracturas ósseas, deformidades músculo-esqueléticas, dor, hipotensão ortostática, 
patologia gastro-intestinal e urológica. Estes sintomas foram escolhidos por acharmos 
serem os mais incapacitantes para os doentes LS-PD, com base nos nossos resultados e os 
já publicados.     
Foram incluídos 50 doentes LS-PD (média de idade 74.1 anos e média de duração de 
doença de 17.9 anos). O quadro motor foi caracterizado por um parkinsonismo grave, 
simétrico e acinético, quase sem rigidez ou tremor. Os sintomas motores axiais foram 
predominantes, com disfagia em 68% dos doentes e gastrostomia em 10%, disartria grave 
em quase todos, e freezing da marcha em 62% e quedas em metade, causando 20% de 
fracturas nos últimos 5 anos. 78% dos doentes necessitavam de cadeira de rodas. A 
pontuação média em on na UPDRS parte motora foi de 49.18 pontos. A levodopa foi 
usada em monoterapia em 1\3 dos doentes, e foi considerada pelos doentes como 
parcialmente eficaz, embora esse benefício não tivesse relevância clínica. A dose baixa 
dos agentes antiparkinsónicos foi possivelmente influenciada pela frequência elevada de 
sintomas cognitivos e comportamentais. As flutuações motoras ocorreram em 78% dos 
doentes e as discinésias em 62%, mas não foram incómodas. Os sintomas não motores 
foram universais, a depressão ocorrendo em 62% e a apatia e a ansiedade em metade dos 
doentes, a demência em 50% e as alucinações em 44%, enquanto que a obstipação 
afectou 82% dos doentes, a disfunção urinária 62% e a hipersudorese um terço. A 
ausência de tremor e de depressão foram os maiores determinantes da presença de 
demência (R2 = 45%; p < 0.01). Os sintomas que maior impacto tiveram na percepção do 
estado de saúde dos doentes foram os sintomas motores axiais e os sintomas não 
motores, resistentes à levodopa. A LHS foi facilmente compreendida e preenchida pelos 
doentes e cuidadores. A sua pontuação média total (0 = handicap máximo; 1 = ausência 
de handicap) foi de 0.33 (SD±0.15), e o seu domínio mais afectado o da Orientação. A 
presença de demência, a pontuação na parte I da UPDRS (sintomas cognitivos e 
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comportamentias) e a pontuação do estádio Hoehn e Yahr em off foram os maiores 
determinantes do handicap (R2 ajustado = 0.62; p = 0.000). Os doentes LS-PD tinham um 
elevado número de co-morbilidades e de doenças anteriores. 70% dos doentes viviam na 
sua casa e 16% estavam institucionalizados, enquanto que 38% tinham um cuidador pago. 
Nos 6 meses precedentes, tinham consultado em média o médico de família 2.2 vezes 
(incluíndo consultas somente para prescrição) e o neurologista 1.7 vezes (incluíndo 
consultas somente para prescrição); 20% faziam fisioterapia e 6% faziam terapia da fala 
ou usufruiam de enfermagem ao domicílio. Os cuidadores informais destes doentes 
relataram uma grande sobrecarga: por semana passavam em média 5 dias (significando 5 
dias x 24h) cuidando dos seus familiares, e reportaram que o impacto médio que a DP 
tinha nas suas vidas era de 3.5 (0 = sem impacto; 4 = impacto máximo). A sua sobrecarga 
estava fortemente correlacionada com o handicap dos doentes, sobretudo com os 
domínios Orientação e Mobilidade. A LHS foi também facilmente compreendida e 
preenchida por 100 doentes em estádio avançado (média de idade 61 anos e média de 
duração de doença de 12.2 anos) e pelos seus cuidadores. A pontuação total média da 
LHS foi inferior à dos doentes LS-PD (0.56 (±0.14)), e os domínios mais afectados o da 
Independência Física e da Integração Social. Os maiores determinantes de handicap 
foram a pontuação média da MDS-UPDRS parte II (aspectos motores das actividades de 
vida diária) em off (p = 0.020), a pontuação média na escala de Schwab e England 
(independência funcional nas actividades de vida diária) em off (p = 0.020) e on (p = 0.05), 
e a pontuação média na escala modificada de AIMS em on (p = 0.042) (escala de 
discinésias) (R2 = 29.6%). 
As características clínicas, a gravidade e determinantes de handicap dos doentes LS-PD 
são muito distintas daquelas dos doentes em estádio avançado, embora hoje em dia 
sejam classificados na categoria genérica de doentes em estádio avançado. Os doentes 
LS-PD estão gravemente incapacitados por sintomas motores axiais e sintomas não 
motores pouco respondedores à levodopa, e estão muito dependentes dos seus 
cuidadores. Os nossos dados e de outros sugerem que os doentes LS-PD constituem um 
sub-grupo muito diferente dos doentes em estádio avançado, e nós propomos uma 
definição operacional para LS-PD ancorada na (perda) independência funcional dos 
doentes nas actividades de vida diária, medida pela escala de Schwab e England em on, 
seja ela causada por manifestações motoras ou não motoras. Infelizmente para estes 
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doentes, encontrámos muito poucos ensaios clínicos controlados que mostrassem a 
eficácia de intervenções farmacológicas ou não farmacológicas para tratar os sintomas 
não motores que mais incapacitam estes doentes. A evidência mais robusta é para o 
tratamento da demência associada à DP (rivastigmina), da psicose (clozapina), da 
osteoporose e prevenção de fracturas (alendronato, risedronato, 1α-hidroxi-vitamina D3) 
e da sialorreia (toxina botulínica, serotipos A e B).  
Os resultados transversais do presente estudo mostram que a LS-PD é um sub-grupo 
distinto dos doentes em estádio avançado da DP, e que os doentes LS-PD têm um quadro 
clínico dominado por um fenótipo motor não-dopaminérgico com grande acinésia 
simétrica e graves sintomas axiais, e por sintomas não motores graves, os quais de forma 
geral não respondem ou respondem pouco à levodopa. A LHS é facilmente compreendida 
e preenchida por doentes com DP e seus cuidadores, e o handicap poderá no futuro ser 
mais explorado na DP como uma medida centrada no doente. Os cuidadores destes 
doentes têm uma grande sobrecarga que está correlacionada com o handicap dos seus 
familiares. Face ao previsível aumento da prevalência de doentes com LS-PD e à ausência 
actual de intervenções terapêuticas eficazes para a maioria dos seus sintomas mais 
incapacitantes, a investigação e alocação de verbas futuras devem focar-se nas 
manifestações da DP não respondedoras à levodopa e nas necessidades de saúde dos 
cuidadores.     
 
 
Palavras-chave: doença de Parkinson; estádio avançado; incapacidade; demência; 
tratamento 
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Parkinson’s disease 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by neuronal loss 
of the dopaminergic neurons of the substantia nigra (SN) pars compacta (SNpc), 
particularly in its lateral ventral tier, associated with Lewy pathology.1-4 However, 
extranigral neuropathology of the cholinergic, noradrenergic and serotonergic systems 
has also been well documented.1-3 Lewy pathology is typified by Lewy bodies, which are 
round α-synuclein immunoreactive eosinophilic inclusions in neuronal perikarya, mostly 
found in the SNpc.1,2,5,6 Lewy pathology is also found in extranigral regions of the central 
nervous system, such as the pons, basal forebrain, limbic cortex or higher order 
association cortices and additionally in the peripheral autonomic nervous system.2,7-9  
The primary cause of PD is still unknown but the concept of PD as a single nosological 
entity is changing to a broader definition that includes different conditions with a 
common clinical final pathway.10 Nevertheless, there is extensive new information 
regarding the aetiology and pathogenesis of PD.11 Environmental exposure, namely to 
pesticides, has been suggested to increase the risk of developing PD.12-17 On the other 
hand, there is a growing number of gene mutations causing monogenic PD (SNCA, PRKN, 
PINK1, DJ-1 and LRRK2).18-26 Whatever the cause of nigral degeneration and formation of 
Lewy bodies, recent evidence shows that pathologic (misfolded) α-synuclein may possibly 
spread from affected to unaffected cells in a prion-like manner, namely from the gut to 
the brain via the vagal nerve, supporting the hypothesis that PD may be a prion-like 
disease.27,28 
PD is the second most common age-related neurodegenerative disorder after Alzheimer’s 
disease. PD occurs worldwide with an age-adjusted prevalence of 1.8% and similar 
incidence in females and males.29 Interestingly, a recent door-to-door survey conducted 
in the Portuguese population aged ≥ 50 years-old found an adjusted prevalence of 0.24% 
and an estimative of the total number of PD cases in Portugal of 180/100.000 inhabitants 
(Nilza Gonçalves, Joaquim J Ferreira, personal communication, February 26, 2015). The 
mean age of onset is 65 years, with prevalence rising from 0.6% at age 65–69 to 2.6–3.5% 
at age 85–89.29,30 Disability is progressive and associated with increased mortality 
(relative risk of death 1.6–3.0 compared with control populations), although considerable 
heterogeneity exists between studies.8,31,32 
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The classical motor features of PD are an asymmetrical bradykinesia, lead pipe type 
rigidity and a 4-6 Hz pill-rolling rest tremor, as well as postural instability later in the 
disease course.33 However, non-motor symptoms (NMS) such as dysautonomia, pain, 
sleep disturbance, depression, psychosis and dementia are now well established features 
of PD and they increase in frequency and severity in later stages of disease.34 The 
pharmacological and surgical therapies substantially improve motor symptoms, but it 
becomes more difficult to achieve satisfactory symptomatic control once patients reach a 
more advanced disease stage. Levodopa (L-dopa) remains the “gold-standard” 
antiparkinsonian drug but its long-term use is associated with the development of 
disabling motor complications, which occur in up to 80% of PD patients.33,35-39 These L-
dopa-induced motor complications (MC) are difficult to treat and impair quality of life 
(QoL) of patients.40 As a rule, NMS do not benefit much with L-dopa and we still lack 
effective treatments for most NMS.41 
Progression and staging of Parkinson’s disease 
Progression 
Classically, and once motor symptoms are manifest, the natural history of PD is regarded 
as the emergence of L-dopa-induced MC and the progression in severity of motor 
symptoms.39,42 Most attention has been given to MC. Indeed, the development of L-dopa-
induced MC is a distinctive marker of PD which was soon noted after the introduction of 
L-dopa to treat parkinsonism.43,44 Most PD patients will develop L-dopa-induced MC, 
namely motor fluctuations and dyskinesias, after an initial phase of sustained and smooth 
response to dopaminergic drugs.39,45,46 The frequency of MC vary considerably, however 
Ahlskog and Muenter39 have found an overall frequency of MC of about 40% after 4-6 
years of L-dopa treatment. The emergence of MC is of paramount importance due to 
their impact on patients’ disability and QoL, caregivers’ burden and a cause of complex 
drugs regimens.47-50 In fact, MC are the major indication for advanced therapies in the 
management of PD, such as functional surgery, apomorphine infusion and L-
dopa\carbidopa intestinal gel pump. Due to their relevance, MC have been a widely 
accepted criterion to define the onset of advanced stage in the progression of PD, and 
much knowledge has been accumulated about MC.39,45,46,51-53 The clinical progression of 
PD is also characterized by an increase in severity of motor symptoms. These motor 
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symptoms can be either L-dopa-responsive or L-dopa-resistant.54,55 Only recently more 
attention has been focused on motor symptoms resistant to L-dopa, which are mostly 
axial in nature such as dysphagia, dysarthria, postural instability and falls.56 However, in 
more advanced PD stages, when disability is most severe, symptoms that are resistant to 
L-dopa seem to contribute more to patients’ disability than MC.  42,56-59 In some patients, 
MC may even remit in later disease stages independently from a reduction in the dose of 
antiparkinsonian drugs.56,59  
In contrast to the classical view, plenty of evidence now shows that NMS increase in 
frequency and severity with disease progression.34,56,60-63 For the most part, these NMS 
are resistant to L-dopa.41 Thus, non-motor and axial symptoms not improved by L-dopa, 
such as dysautonomia, sleep disturbances, dementia, psychosis, apathy, postural 
instability and falls increase in frequency and severity with longer disease duration, and 
they dominate the clinical picture and are the major determinants of patients’ disability in 
more advanced stages of PD.56-58,64-66 In fact, the strongest independent predictors of 
institutionalization and death are dementia, hallucinations, postural instability and 
falls.56,67-72 Additionally, the advent of deep brain stimulation (DBS) to treat MC in the last 
25 years has substantially improved the management of these motor symptoms,73-75 but 
unfortunately it is of little help to treat motor and non-motor symptoms resistant to L-
dopa.76-78 Thus, the classical model of PD progression does not incorporate motor and 
non-motor symptoms resistant to L-dopa, which end up dominating the clinical picture of 
PD as disease progresses. 
Indeed, the pathology model of PD progression in 6 stages by Braak et al1 gives a 
biological rationale for the increase of axial motor and non-motor symptoms resistant to 
L-dopa with the clinical progression of PD. The pathological process begins in the dorsal 
motor nucleus of the glossopharyngeal and vagal nerves and anterior olfactory nucleus, 
and then gradually ascends through the brainstem, anteromedial temporal mesocortex 
and finally the neocortex, thus progressively affecting more brain regions involved in axial 
symptoms and NMS, and more non-dopaminergic systems.1 
Staging 
As a progressive disorder, attempts have been made since long ago to stage the clinical 
evolution of PD.42 Nevertheless, clear-cut and standard definitions of the different stages 
of PD are still lacking, and even experts disagree between them. Usually, the natural 
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history of PD is divided into a Prodromal stage, an Early stage, an Intermediate or 
Moderate stage and an Advanced stage, according to the presence and severity of motor 
symptoms, the overall benefit from antiparkinsonian drugs and the emergence of 
MC.42,45,51,52,79,80 There is no available definition for late-stage PD today. The most widely 
used and accepted definition for advanced stage is the onset of L-dopa-induced MC or, 
alternatively, when MC become severe enough to substantially impair patients’ 
independence in the activities of daily life (ADL) and QoL.45,51,52 According to this clinical 
staging, advanced stage is the last stage in the clinical progression of PD, independently 
of what follows next until patients’ death. But patients with MC do not necessarily 
manifest motor or NMS that are resistant to L-dopa, which is beautifully illustrated by PD 
patients selected to DBS who by definition have the most disabling MC and absence of 
such symptoms as psychosis, dementia, postural instability or falls.81 
The use of the Hoehn and Yahr scale (HY scale) is an alternative way to define advanced 
stage PD.42 In the pre-L-dopa era, Hoehn and Yahr42 developed the staging system that 
bears their name to describe disease progression, combining in the scale the concepts of 
impairment (deficit in a body function or structure) and disability (the functional 
consequence of an impairment) (Figure 1).82 The scale was based on the concept that the 
severity of parkinsonism depended mainly on the presence of bilateral symptoms and 
compromise of gait and balance, and that physical independence was ultimately lost due 
to postural instability, gait disorder and severe bilateral parkinsonism.42,82 The HY scale is 
still the most widely used tool to stage severity of parkinsonism.83 Available data show 
that the HY scale, although anchored on motor signs, is able to capture other important 
features of PD: once patients reach stage 3 (loss of balance) there is a higher risk of 
dementia and decreased survival, and an increase in the scores of the Unified Parkinson`s 
Disease Rating Scale (UPDRS) despite drug adjustment.82,84 On the other hand, it has been 
shown significant correlation between later HY stages and modern measures of motor 
impairment and worse scores in QoL.85,86 Advanced stage PD is commonly defined as 
stages 4 and 5 of the HY scale, which corresponds with loss of physical independence.82 
This scoring is commonly performed during off periods, so that advanced stage PD is 
usually understood as patients in HY stage 4 or 5 during off period. 
Nevertheless, some weaknesses of the HY scale can bias its use as a measure of disease 
progression. Incorporating two indices of severity, impairment and disability, can create 
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ambiguity and difficulty in classifying individual patients, as these indices do not 
necessarily progress in parallel and may even diverge.82 These two indices are heavily 
weighted towards postural instability and lower limbs involvement, which increases the 
likelihood of not capturing disease progression due to other motor or non-motor 
symptoms.82 Additionally, the HY scale is a categorical instrument, implying that an 
increment in stage does not necessarily mean a proportional overall increase in motor 
dysfunction, although in general a progression from stage 1 to 5 reflects global disease 
deterioration.82 The option for 5 stages tends to collapse patients of different impairment 
severity in the same stage, creating clinical heterogeneity in each category of the scale.82 
Finally, as a pre-levodopa instrument, it does not capture MC. In spite of its limitations, 
the HY scale is widely used as a staging system of PD progression owing to the significant 
correlation of its later stages with the presence of symptoms poorly responsive to L-dopa, 
its worldwide acceptance and ease of use thus allowing for effortless replication of 
studies’ results.  
Advanced stage of Parkinson’s disease: current definition and its 
limitations  
As mentioned above, the classic concept of advanced stage PD is broad and depends 
upon the definition used. The most common criteria to define advanced stage PD is either 
the presence of MC or a stage 4 or 5 in the HY scale usually during off period,42,45 
although both can co-exist in a single patient. Depending on the definition used, 
advanced stage denotes different clinical features of PD, either the presence of MC 
or/and the presence of postural instability and physical dependence. In either definition, 
there is no later stage than advanced stage, independently of what happens to patients 
after they start MC or reach HY stage 4 or 5. However, the ELLDOPA trial87 showed that 
MC may develop as soon as within 9 months of L-dopa treatment. Additional 
heterogeneity exists among advanced stage PD patients depending on the predominance 
and severity of non-motor and axial symptoms, and the severity of MC. The heterogeneity 
within the population of advanced stage patients was further incremented with the 
advent of DBS. This surgical technique radically changed the treatment of MC, as a 
powerful intervention to reduce the frequency and severity of MC and disability.74 This 
motor improvement is maintained at least for 10 years with the exception of axial 
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symptoms and NMS, which gradually worsen 3-5 years after DBS.76-78,88,89 For this reason, 
DBS has changed the natural history of advanced stage patients with MC, who no more 
manifest MC but will get further disability once L-dopa resistant symptoms emerge. 
Evidence from clinical practice suggests that a sub-group of advanced stage PD patients 
will progress to a later stage of PD. Despite the severe disability in most advanced stages 
of PD, the clinical characteristics of late-stage PD (LS-PD) have been only partially 
described. This group of patients has very severe motor and non-motor symptoms which 
eventually respond poorly to dopaminergic therapy and for which we lack efficacious 
therapeutical interventions. These patients are dependent on others for ADL and tend to 
seek less often the Movement Disorders Units.  
In our project, we defined LS-PD as patients in HY stage 4 or 5; to further guarantee that 
we would recruit very disabled patients, staging of patients was scored during on period, 
so that LS-PD describes PD patients in HY stage 4 or 5 during the best effect of L-dopa (on 
state).  
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Figure 1. Hoehn and Yahr staging 
 
STAGE 0 = No signs of disease. 
STAGE 1 = Unilateral disease. 
STAGE 2 = Bilateral disease, without impairment of balance. 
STAGE 2.5 = Mild bilateral disease, with recovery on pull test. 
STAGE 3 = Mild to moderate bilateral disease; some postural instability; physically 
independent. 
STAGE 4 = Severe disability; still able to walk or stand unassisted. 
STAGE 5 = Wheelchair bound or bedridden unless aided. 
 
  Later stages of Parkinson’s disease 
36 
 
  
  Aims of the study 
37 
 
AIMS OF THE STUDY 
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The present study aimed to characterize the later stages of PD. The purposes of the study 
were: 
1. To describe the clinical features of PD patients in late-stage. 
2. To determine the handicap and its contributing factors in late-stage PD. 
3. To explore whether the handicap and its determinants in PD patients with 
disabling L-dopa-induced motor complications (advanced stage PD) differ from 
those of PD patients in late-stage. 
4. To propose a definition of late-stage PD in the case these patients do represent a 
new distinct sub-group of advanced stage PD patients. 
5.  To review the therapeutic options for the treatment of NMS in late-stage PD.  
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CHAPTER 1: Clinical features and medication use of Late-Stage PD 
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ABSTRACT 
Background: Studies of late stages of Parkinson`s disease (LS-PD) are limited. To provide 
an adequate health plan for patients in these most advanced stages, accurate information 
on their clinical condition is necessary. 
Objective: Characterize clinical features and medication use of LS-PD.  
Material & Methods: Cross-sectional study of LS-PD stage 4 or 5 of Hoehn & Yahr in on. 
Demographics, clinical features and medication data were obtained using a structured 
questionnaire and physical examination. Patients were asked to grade the perceived 
impact of symptoms on their health status.  
Results: 50 patients (mean age 74.1 years and mean disease duration 17.9 years) were 
studied. Severe akinetic symmetric parkinsonism was present in most, with negligible 
rigidity and tremor, and most patients were wheelchair-bound. Severe postural instability 
and freezing of gait, causing frequent falls and fractures, and prominent dysarthria and 
dysphagia dominated the motor syndrome. Levodopa remained effective in most patients 
in relieving motor symptoms including tremor. Motor fluctuations and dyskinesias were 
present in 78% and 62% of patients respectively, but were not perceived as disabling. All 
had neuropsychiatric and dysautonomic symptoms. Visual hallucinations were present in 
44%, depression in 62% and dementia in 50%. Lack of tremor (p < 0.01) and absence of 
depression (p < 0.01) were independently associated with dementia (R2 = 45%). 
Symptoms causing greatest impact on perceived health status were falls, gait 
unsteadiness, urinary dysfunction and sweats.  
Conclusions: Motor and non-motor non-levodopa responsive problems were frequent 
and the main cause of disability. Fluctuations and dyskinesias were frequent though not 
disabling. Dementia is not unavoidable in these very late stages.  
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INTRODUCTION 
Parkinson`s disease (PD) is a chronic disease with progressive disability. The clinical 
characteristics of late-stage PD (LS-PD), when disability is most severe, have been only 
partially described. In the pre-levodopa era, reporting on the clinical features of 100 
parkinsonian patients, Martin et al58 found that patients in later Hoehn and Yahr (H&Y) 
stages had frequent and severe cognitive decline besides severe motor impairment. In 
recent times, after the introduction of therapies such as levodopa or deep brain 
stimulation, cross-sectional studies have shown worsening of sleep problems, 
dysautonomia and cognition with advancing disease.90,91 The longitudinal studies by Hely 
et al,56-57 describe patients in late-stage PD with common but not disabling dyskinesias 
and on-off, with dementia and dependency on carers eventually occurring in most, whose 
major disability relates to motor and non-motor symptoms not improved by levodopa. 
Better general healthcare, and better understanding of complications and clinical 
management of PD, is likely to increase the prevalence of LS-PD in the future.92 These 
very advanced patients will represent an important burden for families and the 
healthcare system. Since knowledge of the health needs of these disabled patients is 
crucial to plan effective health resources that cover patients and caregivers needs, we 
thought to study the clinical features and handicap of LS-PD patients attending two 
tertiary centres, selected on the basis of motor disability. We report on this paper the 
results concerning the clinical features.    
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PATIENTS & METHODS 
Study participants  
PD patients who attend the movement disorders clinics of two tertiary university 
hospitals were studied. PD was diagnosed according to the UK Parkinson’s Disease Society 
Brain Bank Criteria.93 Patients in stage 4 or 5 of Hoehn and Yahr in on were included 
(stage 4 = patients with severe disability but still able to walk or stand unassisted; stage 5 
= wheelchair bound or bedridden unless aided).42 Patients with a diagnosis of 
parkinsonism other than idiopathic Parkinson`s disease were excluded. The study was 
approved by the local ethical committees. Informed consent was obtained from the 
patient or, if dementia was present, the caregiver.   
Study design  
This was a cross-sectional study performed in two tertiary university hospitals, one in 
Barcelona, Spain (Hospital Clínic Universitari) and other in Lisbon, Portugal (Hospital Santa 
Maria). Consecutive patients were recruited from the outpatient clinics during a 24 
months period. Data were collected by interviewing patients or, if the patient was not 
competent, their caregivers. In those infrequent instances when only the caregiver was 
present in the outpatient clinic, the patient was later evaluated at home by one of the 
authors (MC).  
Patients’ evaluation  
Data on demographics, clinical manifestations and disease management were obtained 
using a structured questionnaire and a physical examination form. Medical charts were 
reviewed when needed.  
Severity of parkinsonism and activities of daily living (ADL) were evaluated using the 
Unified Parkinson`s Disease Rating Scale (UPDRS) and the Schwab & England Scale (S&E), 
respectively.94,95 Part III (motor) of UPDRS was assessed during on period. Parkinsonism 
was considered asymmetric when right-left differences in tremor, bradykinesia and 
rigidity were ≥ 5 points on the UPDRS items 20-23 and 25-26.96 
Levodopa-induced motor and non-motor complications were assessed with part IV of 
UPDRS, the structured questionnaire and the neurological examination. We established 
whether they were present at the time of evaluation, had been present in the past but 
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were currently absent, or had never been present. Patients were asked to rate current 
dyskinesias as either troublesome or not troublesome.  
Non-motor symptoms were assessed in three domains: behavioural and cognition; 
dysautonomia; and other (sleep, fatigue, pain, paresthesias, anorexia, drooling and 
kyphoscoliosis).97 Dementia and depression were diagnosed according to the DSM-IV 
definitions.98 Cognition and mood were rated using the Mini Mental State Examination 
(MMSE) and The Beck Depression Inventory (BDI), respectively.99,100 Orthostatic 
hypotension was defined as a decrease in systolic pressure ≥ 20 mmHg or / and in 
diastolic pressure ≥ 10 mmHg, within 3 minutes of standing. Patients were asked to grade 
the impact caused by symptoms on their perceived health status (0 = none; 4 = 
extreme).97,101 
We obtained data on current medication use and side effects, and patients were asked to 
judge the response of symptoms to levodopa (improves; worsens; no response).  
 
Statistical Analysis  
The software program SPSS 12.0 (SPSS, Chicago, IL) was used for database and statistical 
analysis. We performed a descriptive analysis for each variable. Comparison of cohorts 
from Lisbon and Barcelona was done, using Independent Samples T Test and Mann-
Whitney U Test for comparison of continuous variables, and Pearson Chi-square Test and 
Fisher Exact Test for differences in proportions. Concerning the impact caused by 
symptoms on patients` perceived health status, we calculated the median value (0 = 
none; 4 = extreme) for each symptom reported by patients. Variables associated with 
dementia (dependent variable) at a significance level of p ≤ 0.1 were included in a 
multivariate logistic regression analysis, using likelihood ratio forward stepping. Two-
tailed p values < 0.05 were considered significant.  
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RESULTS 
Fifty patients were included (Barcelona 28, Lisbon 22). Demographic data are shown on 
Table 1. Disease characteristics were comparable in the two groups of patients, except for 
medication (see below).  
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Manifestations  
Motor Symptoms 
As expected, slowness of movement occurred in all patients, and was severe in most 
(Table 2). Arm rest tremor was present in 8 (16%) (severe in 1), and also affected lower 
limbs in 2. Mild postural tremor was observed in 25 (50%) patients, including all the 
patients with rest tremor. Limb rigidity was detected in 32 patients (64%), and was mild in 
most. All patients had postural instability in accordance with selection criteria for the 
study. 
Freezing of gait was reported by 31 patients (62%), and in 15 it was frequent and a cause 
of falls. Falls occurred in 25 (50%), and in 14 cases they occurred daily. Of those 25 
patients, 20 were H&Y stage 4 and 5 were H&Y stage 5. Forty-eight (96%) reported 
problems with speech, which was difficult to understand or unintelligible in 26. Dysphagia 
was reported by 34 (68%). Ten experienced occasional choking, thirteen required soft 
food, seven had a nasogastric tube, and in five feeding was through a gastrostomy.  
Table 1 Demographic characteristics and Hoehn & Yahr stage score in late-stage PD patients  
Characteristic PD patients  
n 50 
Age (years) (mean (SD))  74.1 (7.0) 
Women (n (%)) 27 (54) 
Age at disease onset (years) (mean (SD)) 56.2 (10.4) 
Duration of disease (years) (mean (SD)) 17.94 (6.3) 
Education (years) (mean (SD)) 7.6 (4.7) 
Hoehn & Yahr stagea (nº (%)) 
4 
5 
 
30 (60) 
20 (40) 
Abbreviations: PD, Parkinson`s disease 
a scored in on period. 
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At the time of evaluation, 72% of patients perceived that levodopa improved mobility, 
and 90% that it improved tremor. 73% of patients thought levodopa had no effect on 
unsteadiness, and 16% had the perception levodopa worsened falls. Still, 52% thought it 
improved freezing. Though 37% of patients reported some benefit from levodopa on 
speech, dysphagia did not improve among 82%. 
 
 Abbreviations: UPDRS, Unified Parkinson`s Disease Rating Scale; PD, Parkinson`s disease. 
a Higher numbers indicate a greater severity of impairment.  
 
Table 2 Motor symptoms in late-stage PD patients 
 PD patients (n = 50) 
Asymmetric disease (n (%)) 16 (32) 
Slowness of movement (n (%)) 50 (100) 
UPDRS limb bradykinesia items, mediana 3 
Postural instability (n (%)) 50 (100) 
Dysarthria (n (%)) 48 (96) 
UPDRS speech, mediana 3 
Neck rigidity (n (%)) 39 (78) 
UPDRS neck rigidity, mediana 2 
Dysphagia (n (%)) 34 (68) 
UPDRS swallowing, mediana 2 
Limb rigidity (n (%)) 32 (64) 
UPDRS limb rigidity items, mediana 1 
Freezing (n (%)) 31 (62) 
Falls (n (%)) 25 (50) 
Tremor (n (%)) 25 (50) 
Rest tremor (n (%)) 8 (16) 
Asymmetric rest tremor (n (%)) 7 (14) 
Postural tremor (n (%)) 25 (50) 
Head tremor (n (%)) 2 (4) 
UPDRS tremor items, mediana 0 
Fixed dystonia (n (%)) 24 (48) 
Bone fractures in the previous 5 years (n (%)) 10 (20) 
Need for a wheelchair (n (%)) 39 (78) 
Gastrostomy (n (%)) 5 (10) 
UPDRS motor on (mean (SD))a 49.18 (13.0) 
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Levodopa-induced motor complications 
Levodopa-induced motor complications were present in 39 patients (78%) at the time of 
the study (motor fluctuations in 39; dyskinesias in 31) (Table 3). They had occurred in an 
additional eight patients (motor fluctuations in 8; dyskinesias in 2) at some point during 
the disease course but had later remitted. Wearing-off occurred in all 39 patients. Offs 
occupied < 25% of the day in 19, 26-50% of the day in 8, and > 75% of the day in 7 
patients. The mean difference in UPDRS ADL score (n=39) between on and off was 
statistical significant (p < 0.05), and the same was found for the Schwab & England Scale 
(n=39) (p < 0.01) (Table 4). 
Dyskinesias were troublesome in 13 (26%), but in only 4 they were severely disabling 
(UPDRS score 3 or 4). Dyskinesias occupied < 25% of the day in 17, and > 75% of the day 
in 4 patients.  
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Table 3 Levodopa-induced complications in late-stage PD patients at the time of study assessment 
 PD patients (n = 50) 
L-dopa-induced motor complications (n (%)) 39 (78) 
Wearing-off (n (%)) 39 (78) 
Off duration > 75% of the day (n (%))  7 (14) 
No on response (n (%)) 17 (34) 
Morning dystonia (n (%)) 11 (22) 
Off dystonia (n (%)) 9 (18) 
Delayed on response (n (%)) 7 (14) 
Morning akinesia (n (%)) 5 (10) 
On/off phenomena (n (%)) 2 (4) 
Dyskinesia (n (%)) 31 (62) 
peak-dose (n (%)) 15 (30) 
diphasic (n (%)) 9 (18) 
square-wave (n (%))  7 (14) 
  Troublesome dyskinesias (n (%)) 13 (26) 
Dyskinesia duration > 75% of the day (n (%))  4 (8) 
Severe or complete disabling dyskinesia (n (%)) 4 (8) 
L-dopa-induced non-motor fluctuations (n (%)) 33 (66) 
Neuropsychiatric (n (%)) 24 (48) 
Disautonomic (n (%)) 11 (22) 
Sensory (n (%)) 8 (16) 
UPDRS part IV (mean (SD))a 5.3 (3.5) 
Abbreviations: UPDRS part IV, treatment complications component of Unified Parkinson`s Disease Rating 
Scale; PD, Parkinson`s disease; L-dopa, levodopa. 
a Higher numbers indicate a greater severity of impairment.  
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Cognition, Mood and Behaviour  
Neuropsychiatric symptoms were present at the time of examination in all patients (Table 
5). Visual hallucinations and delusions had occurred in an additional 22 and 9 patients, 
respectively, at some point during the disease course but had later remitted.  
Thirty-one patients (62%) were depressed. Nineteen depressed patients also reported 
symptoms suggestive of apathy.  
Dementia was present in 25 (50%) patients. Mean MMSE score in 22 demented patients 
was 11.8 (SD ± 6.5), while it was 23.5 (SD ± 4.5) in the non-demented. The MMSE cut-off 
score is adjusted to literacy in Spain and Portugal and the above value of 23.5 points does 
not configure dementia in those populations. Thirteen demented patients reported visual 
hallucinations and 10 delusions. Variables (univariable analysis) that were statistically 
significantly  associated with the presence of dementia were lack of tremor (p < 0.01), 
absence of depression (p < 0.01), symptoms suggestive of apathy (p < 0.01), daytime 
somnolence (p < 0.05), absence of irritability (p < 0.05), less consumption of 
antiparkinsonian drugs (p < 0.01), and worse scores on UPDRS ADL part  (p < 0.01), UPDRS 
part IV (p < 0.05) and S&E scale (p < 0.05). In a multivariable logistic regression analysis, 
Table 4 Performance in the activities of daily living of Late-Stage PD patients. 
Activities of daily living 
 
 
UPDRS ADL (mean (SD))a 
on 
off 
 
 
28.2 (6.3) 
29.6 (5.8) 
 
 
p < 0.05c 
S&E (mean (SD))b 
on 
off 
 
31.0 (15.7) 
23.2 (14.2) 
 
 
p < 0.01c 
Abbreviations: UPDRS, Unified Parkinson`s Disease Rating Scale; ADL, activities of daily living; 
S&E, Schwab and England scale;  
a Higher numbers indicate a greater impairment.  
b Higher numbers indicate more independency in the activities of daily living. 
c Not considered clinical relevant 
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lack of tremor (p < 0.01) and absence of depression (p < 0.01) remained independently 
associated with dementia. This model could predict the presence of dementia in 72% of 
the cases and explained its occurrence in 45% (Nagelkerke R Square).  
Neuropsychiatric symptoms severity changed with levodopa intake in 48% of patients 
(Table 3). Improvement after a levodopa dose was reported in sadness (13.5% of 
patients), apathy (32%), slowness of thinking (44%), anxiety (25%), and irritability (37%). 
Worsening of anxiety and irritability was reported by a small proportion of patients (8% 
and 5%, respectively). Aggressive behaviour was mostly (75%) unaffected by levodopa. 
 
Dysautonomic complications 
Dysautonomic symptoms occurred in 48 patients (96%) (Table 5). We measured arterial 
blood pressure in 18 and documented orthostatic hypotension in 3. 
 
Pain, sleep and other symptoms 
Sleep disturbances were very frequent and sensory symptoms were reported by 19 
patients (38%) (Table 5).  
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Table 5 Non-motor complications in late-stage PD patients 
 PD patients (n = 50) 
Cognition, Mood & Behaviour (n (%)) 50 (100) 
Depression (n (%)) 31 (62) 
BDI in 15 testable depressed patients (mean (SD)) 16.8 (5.29) 
Symptoms suggestive of apathy (n (%)) 28 (56) 
Slowness of thinking (n (%)) 25 (50) 
Anxiety (n (%)) 25 (50) 
Dementia (n (%)) 25 (50) 
MMSE in 44 testable patients (demented and non-demented) (mean (SD)) 17.7 (8.1)  
MMSE in 22 demented patients (mean (SD)) 11.8 (6.5) 
MMSE in 22 non demented patients (mean (SD)) 23.5 (4.5) 
Visual hallucinations (n (%)) 22 (44) 
Irritability (n (%)) 20 (40) 
Delusions (n (%)) 16 (32) 
Aggressive behaviour (n (%)) 8 (16) 
UPDRS part I (mean (SD))a 6.4 (3.9) 
Dysautonomic complications (n (%)) 48 (96) 
Constipation (n (%)) 41 (82) 
Urinary dysfunction ((incontinence, urgency or retention) (n (%)) 32 (64) 
Hyperhidrosis (n (%)) 18 (36) 
Sweats (n (%)) 18 (36) 
Orthostatism (item 42 of UPDRS) (n (%)) 13 (26) 
Dyspnea (n (%)) 7 (14) 
Syncope (n (%)) 4 (8) 
Pain, Sleep & other symptoms - 
Night sleep problems (n (%)) 30 (60) 
Diurnal somnolence (n (%)) 18 (36) 
Pain (n (%)) 12 (24) 
Anorexia (n (%)) 11 (22) 
Paresthesias (n (%)) 10 (20) 
Sleep attacks (n (%)) 5 (10) 
Weight loss (n (%)) 7 (14) 
Fatigue (n (%)) 18 (36) 
Drooling (n (%)) 35 (70) 
Kyphoscoliosis (n (%)) 8 (16) 
Abbreviations: MMSE, Mini Mental State Examination; BDI, Beck Depression Inventory; UPDRS, Unified 
Parkinson`s Disease Rating Scale; PD, Parkinson`s disease.a Higher numbers indicate a greater severity of impairment.  
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Impact of symptoms on perceived health status  
Symptoms causing an extreme or severe impact on patients` perceived health status were 
in most instances motor and non-motor symptoms that do not respond to levodopa 
(Table 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medication 
At the time of the study, 49 patients (98%) were taking levodopa, as monotherapy (n = 
18) or in combination with other antiparkinsonian drugs (n = 31) (Table 7). Mean daily 
doses of  ropinirole  was 6 ± 3.6 mg/d;  of  pergolide 1.8 ± 1.2 mg/d; of pramipexole 0.68 ± 
0.42 mg/d; of cabergoline 2.5 ± 2.4 mg/d; of  bromocriptine 10.7 ± 5.1 mg/d and of 
piribedil 150 ± 0.0 mg/d. Statistical significant differences between the Lisbon and 
Barcelona cohorts were found in the frequency of patients on bromocriptine (Lisbon= 6 vs 
Barcelona= 1 patients; p = 0.04) and in the mean daily dose of levodopa (Lisbon= 934 ± 
352.5 mg vs Barcelona= 688 ± 234.4 mg; p = 0.01). The mean daily dose of levodopa did 
not differ significantly between patients with and without motor complications. Twenty-
five patients (50%) were taking atypical neuroleptics because of delusions and visual 
hallucinations. Fifteen of them were demented. Clozapine was the most frequently 
prescribed neuroleptic (n = 19), at a mean daily dose of 56.5 ± 71.0 mg/d, while 
Table 6 Symptoms causing an extreme or severe impact on patients` perceived health status in 
Late-Stage PD patients. 
Impact of symptoms on patients` perceived 
health status 
 
Symptoms with extreme impact  
(score 4) 
falls 
unsteadiness 
urinary dysfunction 
sweats 
Symptoms with severe impact  
(score 3) 
bradykinesia 
freezing 
speech problems 
dysphagia 
 
apathy 
anxiety 
depression 
dementia 
constipation 
dyspnea 
pain 
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quetiapine was prescribed in 5 patients (mean daily dose 125 ± 90.1 mg/d). Fourteen 
patients (28%) were on antidepressants, while nearly half were on benzodiazepines: 56% 
because of anxiety and 50% because of nocturnal sleep disturbances.  
 
 
 
Table 7 Medication in late-stage PD patients 
 PD patients (n = 50) 
Levodopa (n (%)) 
total 
monotherapy 
in combination 
 
49 (98) 
18 (36) 
31 (62) 
Daily dose of levodopa (mg) (mean (SD))  785 (318) 
Range of daily dose of levodopa (mg) 250-1900 
Agonists (n (%)) 25 (50) 
Amantadine (n (%)) 9 (18) 
Entacapone (n (%)) 6 (12) 
Selegiline (n (%)) 5 (10) 
Anticholinergics (n (%)) 1 (2) 
Brain surgery for PD (n (%)) 4 (8) 
Neuroleptics (n (%)) 25 (50) 
Benzodiazepines (n (%)) 22 (44) 
Antidepressants (n (%)) 14 (28) 
Rivastigmine (n (%)) 2 (4) 
Non neurological medication (n (%)) 32 (64) 
Abbreviations: PD, Parkinson`s disease 
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DISCUSSION  
As expected, we have found that this cohort of LS-PD had long-standing disease, with 
severe motor and frequent and severe non-motor symptoms. Levodopa-induced motor 
complications were frequent but generally not disabling. Symptoms causing the highest 
disability, such as falls, postural instability and many non-motor symptoms, were non-
levodopa responsive. Medication was mainly targeted at improving motor symptoms, 
and, in two-thirds of patients, consisted of levodopa associated with other 
antiparkinsonian drugs. Dosage of these drugs was probably influenced by the frequent 
occurrence of neuropsychiatric symptoms, such as psychosis. Although patients reported 
some benefit from levodopa, this was of limited clinical relevance. The scores in UPDRS-
ADL and S&E in on and off, although statistical significant, showed that patients were 
highly disabled and dependent on caregivers in either levodopa state. Other treatments 
were directed to the correction of psychosis, anxiety, sleep disturbances and depression.  
Our data do give some insight about the clinical characteristics of LS-PD and may have 
implications on how we manage their illness. Information on clinical features of LS-PD is 
relatively sparse.42,56-59,90 Papapetropoulos and Mash59 have reported on the frequency of 
motor complications on a cohort of 61 patients with LS-PD, although only two thirds of 
their patients were H&Y greater than 3. Recently, The Sydney Multicenter Study reported 
on the 30 patients surviving after 20 years of follow-up, most in H&Y stage 4.57 These 
patients were initially recruited into a clinical trial, which may have influenced entrance 
characteristics and subsequent management.  
The cohort  
We selected patients based on motor PD severity, and not disease duration. The mean 
disease duration (18 years) was longer than previously reported in other studies that 
included severely disabled patients.56,69,102 However, age at disease onset was similar, 
excluding early disease onset as the cause of prolonged survival.56,58,102 We included more 
females than males. This excess of women might be related to shorter life expectancy of 
men compared to women. 
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Patients` perceived health status and ADL 
The symptoms most contributing to diminished perceived health status, in line with other 
reports, were mostly non-levodopa responsive, and for the majority we lack efficacious 
therapeutic interventions.56,57 And even for the ones where treatment is available, such 
as depression and anxiety, about half were not prescribed any treatment, suggesting that 
clinicians may have under-recognized or underestimate these symptoms.  
Motor symptoms 
Most patients had symmetric disease, possibly a sign of PD progression.96 Bradykinesia 
had a profound impact on patients` disability, while rigidity was generally mild and rest 
tremor was uncommon. Falls and related fractures (20%) were common but perhaps 
lower than expected, probably since the majority of patients (78%) were wheelchair-
bound. Our findings are in line with those of a recent meta-analysis, that found a 3-month 
fall rate of 46% and that falls decreased in later stages of disease.103 Dysarthria had a 
great impact on patients` condition, interfering with communication with caregivers, 
whereas dysphagia was a frequent cause of choking and tube feeding. Pneumonia, 
frequently caused by aspiration, was the most common cause of death in the Sydney 
cohort, suggesting that an aggressive intervention on dysphagia might prolong 
survival.56,57,104 
Levodopa-induced motor complications 
Overall, levodopa-induced motor complications occurred frequently in our cohort (78%), 
findings similar to those from Papapetropoulos and Mash59 (88.5%) and from the Sydney 
studies (95%).56,57 In our cohort, offs were characterised by high disability and 
dependency on caregivers, although they were of short duration. Even so, patients did 
not value the relative impact of offs compared to ons, probably because they also were 
doing poorly in the on state. Dyskinesias were frequent, but troublesome in only a 
minority, and patients were free of dyskinesias for most of the day. Likewise, in the study 
of Papapetropoulos and Mash,59 dyskinesias (60.6%) were severe in only 6 cases. The 
Sydney studies also reported not disabling levodopa-induced motor complications.56,57 
They occurred in most at either 15 and 20 years, but severe dyskinesias only afflicted 10% 
of patients, and in just 17% an off > 75% of the day was reported.56,57 
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LS-PD cohorts with a high frequency of motor fluctuations, as ours, may represent a 
subset of LS-PD with long survival. When comparing moderate-severe motor fluctuators 
with non-fluctuators, Kempster et al105 found that the development of disease milestones 
(falls, hallucinations, cognitive disability and institutionalization) was determined solely by 
age, not disease duration or presence of fluctuations. Fluctuators had a significantly 
longer disease duration when they reached milestones.105 Our cohort reinforces that 
patients with fluctuations reach milestones as do patients without fluctuations.  
Non-motor complications of PD  
Non-motor symptoms, mostly neuropsychiatric and dysautonomic, were prominent in 
our cohort. The number of patients with neuropsychiatric symptoms was higher than the 
one reported by Aarsland et al60 (61%), where only a 23% of patients were in a Hoehn & 
Yahr stage of 4, suggesting that more advanced disease is associated with a higher 
frequency of neuropsychiatric symptoms. However, the type and relative frequency of 
symptoms were similar, indicating that the presence of most symptoms is independent of 
staging.60,106  
Our figure (62%) for depression is similar to that found in the Sydney studies,56,57 but 
higher than the 43% reported by Papapetropoulos et al,90 in a retrospective study. 
Possibly, the prominent dysarthria, cognitive impairment, severe hypomimia and apathy 
might have biased this figure.107 
Almost half (44%) had visual hallucinations at the time of study assessment, consistent 
with the late stage of their illness.56,57,90,91,108,109 The presence of hallucinations probably 
explains the low doses of agonists, and frequent use of levodopa as monotherapy. 
Hallucinations were a major cause of morbidity, as 55% of those with hallucinations rated 
them as causing an extreme or severe impact on their perceived health status. This severe 
disability is also indirectly expressed in the widespread use of neuroleptics (50%).  
Only 50% of the patients were diagnosed with dementia, percentage lower than in other 
series that claim inevitability.57 Diagnosis of dementia was based on clinical examination 
and not on neuropsychological assessment, and this might explain the differences 
reported. Our frequency is similar to that found in the Sydney study56 at 15 years (48%), 
by Papapetropoulos  et al90 (50.7%), and by Kempster et al105 (55.6%). It differs from that 
in the Sydney cohort at 20 years57 (83%), but in this study the duration of PD was longer, 
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even though the mean age of patients was similar to ours. Besides that, in the Sydney 
cohort 26 patients were already demented at baseline neuropsychological assessment.57 
It also differs from the one found by Aarsland  et al61 after 8 years of follow-up (78%). 
However, these authors61 calculated the period prevalence and not point prevalence, 
combining prevalence, incidence and mortality rates. Importantly, the data from Hely et 
al57 and Aarsland et al61  are longitudinal which increments its reliability compared to our 
cross-sectional data collection.  
Lack of tremor and absence of depression independently predicted the presence of 
dementia. Published data has shown better prognosis and preserved cognition in tremor-
predominant PD.110,111 Depression has been found to correlate variably with cognitive 
decline.56,112-114 We may assume that demented patients are less likely to report or show 
depression, and that could be an explanation to our findings. As some studies suggest 
that depression associates with cognitive decline, longitudinal data are essential to 
disclose how depression and dementia relate to each other at different stages of 
cognitive function. 
Forty-eight patients (96%) had symptoms suggestive of autonomic dysfunction. In a 
quarter, orthostatism was symptomatic, but syncope was rare, and none was under 
specific treatment. Prominent urinary dysfunction and constipation, as well as sweats, 
were very common, and responsible for severe disability. Night sleep problems were not 
significantly troublesome, contrary to common belief. Pain was uncommon but very 
disabling, unlike results of two cross-sectional studies that reported higher pain 
frequencies (62-70%), even though in patients less advanced than ours`.115,116  
Medication 
Nearly all patients took levodopa either on monotherapy or in association with other 
antiparkinsonian drugs, mainly dopamine agonists at low doses. The mean dose of 
levodopa was in the same range of that in the Sydney cohort56,57 and in the study by 
Papapetropoulos and Mash59, but much lower than the mean dose of advanced PD 
patients that are candidates to deep brain stimulation (about 1100 mg).74,117 Overall, 
patients still reported some benefit from levodopa intake, namely in motor slowness and 
tremor. Patients with motor fluctuations had however “poor” ons, with a change in 
disability between on and off that was of little clinical relevance. Similar to reported by 
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others, a small portion of our patients had a remission of motor fluctuations.59 Although 
we can not ruled out that changes in doses or pattern of the dopaminergics treatment 
can be responsible for such remission, this finding could be also explained by increasing 
extranigral pathology along with the disease progression.1,118   
Shortcomings 
We studied a convenience sample of hospital-based patients, who were under the care of 
our tertiary clinics. Our recruitment rate was low (25 patients per year per centre), which 
strongly suggests that patients withdraw from specialized medical care once they reach 
an advanced stage. Our results, then, may not be representative for the entire population 
of LS-PD, namely, we cannot draw any firm conclusion regarding the prevalence of 
dementia in these late stages of the disease. Additionally, recruiting patients from two 
countries could have led to a heterogeneous sample. Nonetheless, except in the use of 
antiparkinsonian drugs, which most likely reflects different prescription practices, the 
sample was rather homogeneous. 
Conclusions 
In this hospital-based cohort of LS-PD patients, both motor and non-motor non-levodopa 
responsive problems were the main cause of disability. Half of the patients were 
considered non-demented, questioning the inevitability of dementia at late-stage. 
Levodopa-induced motor complications were frequent though not generally disabling, 
possibly since swings between on and off were of small magnitude. Future interventions, 
either pharmacological or non-pharmacological, and research and allocation of funds 
must focus on non-levodopa responsive aspects of the disease. 
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ABSTRACT 
Background: Handicap has not been explored as a patient-centred outcome measure in 
Parkinson’s disease (PD).  The clinical features and medication use in late stages of PD (LS-
PD) were reported previously. Material & Methods: Handicap, medical conditions, use of 
healthcare resources and the impact of LS-PD upon caregivers were characterized in a 
cross-sectional study of LS-PD stages 4 or 5 of Hoehn and Yahr (H&Y). Handicap was 
measured using the London Handicap Scale (LHS; 0=maximal handicap; 1=no handicap). 
Results: The mean LHS score in 50 patients was 0.33 (SD±0.15). The presence of 
dementia, the UPDRS part I score and H&Y stage in off independently predicted the LHS 
score (adjusted R2=0.62; p=0.000). Co-morbidities and past medical conditions were 
frequent. Thirty-five patients lived at their house. Forty-five received unpaid care. Mean 
visits to family doctor in preceding 6 months were 2.2 (SD±3.0) and to neurologist 1.7 
(SD±1.0). Use of other health resources was low. Unpaid caregivers spent much time with 
patients and reported a high burden. Conclusion: Handicap could be measured in LS-PD 
and LHS was easily completed by patients and caregivers. The high handicap in our cohort 
was mostly driven by the presence of dementia, behavioural complaints and the severity 
of non-dopaminergic motor features. Patients visited doctors infrequently and made low 
use of health resources, while unpaid caregivers reported a high burden.  
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INTRODUCTION 
There are few published studies on late-stage Parkinson’s disease (LS-PD).57,58 A hospital-
based population of LS-PD has recently been reported by us.119 These subjects were 
severely disabled mostly from non-levodopa responsive problems, and suffered frequent 
motor fluctuations and dyskinesias. 
The impact that PD has on patients has been addressed using several outcome measures, 
such as disability, interference in activities of daily living (ADL) or quality of life 
(QoL).101,123,124 Handicap, an outcome measure widely used in chronic neurological or 
non-neurological diseases,125,126 has never been used in PD. The World Health 
Organization (WHO) defines handicap as “(…) a disadvantage for a given individual, 
resulting from an impairment or a disability, that limits or prevents the fulfilment of a role 
that is normal, depending on age, sex, and social and cultural factors, for that 
individual”,127 and thus it is central to the management of patients with chronic 
diseases.128 Handicap seems a more understandable concept to patients than QoL and a 
more meaningful measure of the impact of disease in the health status (HS) of an 
individual patient. The London Handicap Scale (LHS) is one of the most frequently used 
instruments to measure handicap126,129,130 but has never previously been used in PD. It 
has proven good validity, reliability, sensitivity to change and transcultural validation.129-
132  
The results concerning handicap caused by very advanced PD are reported. In addition, 
the presence of co-morbidities and past medical conditions, health resources use and the 
impact of disease on caregivers are described. 
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PATIENTS & METHODS 
Objectives:  
Primary: quantify the handicap of a hospital-based population of LS-PD patients and to 
identify its determinants. Secondary: determine co-morbidities and past medical 
conditions; quantify the use of health resources; assess the impact of disease upon the 
caregivers. 
Study participants  
PD patients attending the movement disorders outpatient clinics of two university 
hospitals, one in Barcelona, Spain (Hospital Clínic Universitari) and other in Lisbon, 
Portugal (Hospital Santa Maria). PD was diagnosed according to the UK Parkinson’s 
Disease Society Brain Bank Criteria.93 Patients in stage 4 or 5 of Hoehn and Yahr (H&Y) in 
on were included (stage 4 = patients with severe disability but still able to walk or stand 
unassisted; stage 5 = wheelchair bound or bedridden unless aided).42 Patients’ informal 
caregivers (unpaid caregivers) were interviewed. The study was approved by the local 
ethical committees and written informed consent was obtained.   
Study design  
A cross-sectional study in subjects consecutively recruited during a 24-months period.  
Participants’ evaluation  
Patients 
Data on demographics, clinical manifestations and disease management, co-morbidities 
and past medical conditions, and usage of healthcare resources were obtained using a 
structured questionnaire (interviewing the patients and caregivers), a physical 
examination form and review of medical charts when needed. Details of other 
assessments performed in this same group of patients have been reported previously.119 
Briefly, patients were evaluated using the Unified Parkinson’s Disease Rating Scale 
(UPDRS) and the Schwab & England Scale (S&E)94; a structured questionnaire adapted 
from Witjas et al97 to assess non-motor symptoms in three domains: behavioural and 
cognition; dysautonomia; and other (sleep, fatigue, pain, paresthesias, anorexia, and 
drooling); dementia and depression were diagnosed according to the DSM-IV definitions98 
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and rated using the Mini Mental State Examination99 and The Beck Depression 
Inventory,100 respectively.  
Handicap was assessed using the LHS.129,130 This scale was developed to determine the 
effect of chronic disease on a person’s functional ability.126,129-132 It takes around 10 
minutes to be completed, and consists of a self-completed questionnaire, though the 
descriptions of questions are objective enough for completion by a proxy. The 
questionnaire has 6 questions, one for each domain of handicap (mobility, physical 
independence, occupation, social integration, orientation, and economic self sufficiency) 
and each question contains six sentences hierarchically describing the degree of 
handicap; for each question, the patient must choose the most suitable sentence. Each 
sentence is assigned a scale weight. The questionnaire comprises a matrix of scale 
weights which when combined give a total score for handicap, to which a constant value 
of 0.456 is added; the final score ranges from 0 (maximal handicap) to 1 (no handicap).  
Caregivers 
Informal caregivers were asked to rate the impact of PD on their life (0 = no impact; 4 = 
maximal impact)97 and the time per week they spent caregiving. The time allocated to 
caregiving was calculated by multiplying number of hours per day x number of days per 
week. 
Statistical Analysis  
The software program SPSS 14.0 (SPSS, Chicago, IL) was used. We performed a descriptive 
analysis of demographic data, of motor symptoms according to UPDRS and structured 
questionnaire and NMS according to structured questionnaire adapted from Witjas et 
al,97 of the impact of symptoms on perceived HS (impact on perceived HS rated by 
patients, 0 = no impact; 4 = extreme impact),119 of medication use, of associated medical 
conditions, of patients’ residency (“own home”, “relatives’ home” or “nursing home”) and 
use of health resources, and of caregiver burden according to time allocated to caregiving 
and the impact of PD on caregivers’ life. A descriptive analysis of the LHS total score and 
sub-scores was performed. 
Comparison of cohorts from Lisbon and Barcelona was done. Independent Samples T Test 
and Mann-Whitney U Test were used for comparison of continuous variables, and 
Pearson Chi-square Test and Fisher Exact Test for differences in proportions. Univariable 
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analysis was performed, and variables associated with the LHS score at a significance level 
of p ≤ 0.1 were entered in a multiple linear regression analysis using the LHS total score as 
dependent variable. Two-tailed p values < 0.05 were considered significant.  
 
  
  Handicap in Late-stage PD 
71 
 
RESULTS 
Patients 
Fifty patients were studied. Results on demographics, clinical manifestations and 
medication use have been reported previously119 and shown in Tables 1 and 2.  
 
Table 1 Demographics and medication use in late-stage PD patients  
Characteristic  PD patients (N = 50)  
Female (n (%))  27 (54)  
Patients from Barcelona (n (%))  28 (56) 
Patients from Lisbon (n (%))  22 (44) 
Age (years) (mean (SD))  74.1 (7.0)  
Duration of disease (years) (mean (SD))  17.94 (6.3)  
Hoehn & Yahr stage
a
 (nº (%)) 
   4 
   5  
 
30 (60) 
20 (40)  
Levodopa (n (%))  
   monotherapy  
   in combination  
49 (98)  
18 (36)  
31 (62)  
Daily dose of levodopa (mg) (mean (SD))  785 (318)  
Range of daily dose of levodopa (mg)  250-1900  
Agonists (n (%))  25 (50)  
Amantadine (n (%))  9 (18)  
Entacapone (n (%))  6 (12)  
Selegiline (n (%))  5 (10)  
Anticholinergics (n (%))  1 (2)  
Brain surgery for PD (n (%))  4 (8)  
Neuroleptics (n (%)) 
   clozapine (n (%)); daily dose (mg) (mean (SD)) 
   quetiapine (n (%)); daily dose (mg) (mean (SD)) 
   other (n (%))  
25 (50) 
19 (38); 56.5 (71.0)  
5 (10); 125 (90.1)  
1 (2)  
Benzodiazepines (n (%))  22 (44)  
Antidepressants (n (%))  14 (28)  
Rivastigmine (n (%))  2 (4)  
Non neurological medication (n (%))  32 (64)  
Abbreviations: PD, Parkinson’s disease; a Scored during on period 
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Table 2 Clinical manifestations in late-stage PD patients  
Clinical manifestation  PD patients (N = 50)  
UPDRS motor on (mean (SD))
b
  49.18 (13.0)  
UPDRS ADL (mean (SD))
b
 
   on 
   off  
28.2 (6.3) 
29.6 (5.8)  
S&E (mean (SD))
c
 
   on 
   off  
31.0 (15.7) 
23.2 (14.2)  
Asymmetric disease (n (%))  16 (32)  
UPDRS limb bradykinesia items, median
b
  3  
Limb rigidity (n (%))  32 (64)  
Rest tremor (n (%))  8 (16)  
Postural tremor (n (%))  25 (50)  
Postural instability (n (%))  50 (100)  
Freezing (n (%))  31 (62)  
Falls (n (%))  25 (50)  
UPDRS speech, median
b
  3  
UPDRS swallowing, median
b
  2  
L-dopa-induced motor complications (n (%))  39 (78)  
    Wearing-off (n (%))  39 (78)  
   off duration > 75% of the day (n (%))  7 (14)  
    Dyskinesia (n (%))  31 (62)  
    Troublesome dyskinesias (n (%))  13 (26)  
L-dopa-induced non-motor fluctuations (n (%))  33 (66)  
Cognition, mood and behavior (n (%))  50 (100)  
     Visual hallucinations (n (%))  22 (44)  
     Delusion (n (%))  16 (32) 
     Dementia (DSM-IV) (n (%))  25 (50)  
     MMSE (mean (SD)) 17.7 (8.1) 
     Anxiety (n (%))  25 (50)  
     Irritability (n (%))  20 (40)  
     Aggressive behavior (n (%))  8 (16)  
     Depression (DSM-IV) (n (%))  31 (62)  
     BDI  (mean (SD)) 16.8 (5.29) 
     Symptoms suggestive of apathy (n (%))  28 (56)  
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     UPDRS part I (mean (SD))
b
 6.4 (3.9) 
Dysautonomic complications (n (%))  48 (96)  
     Orthostatic hypotension
d
 (n (%))    3 (6) 
     Orthostatism (item 42 of UPDRS) (n (%))  13 (26) 
     Syncope (n (%))  4 (8)  
     Constipation (n (%))  41 (82) 
     Urinary dysfunction 
   (incontinence, urgency or retention) (n (%)) 
32 (64)  
     Hyperhidrosis (n (%))  18 (36) 
     Sweats (n (%))  18 (36) 
     Dyspnea (n (%))  7 (14) 
Night sleep problems (n (%))  30 (60)  
Diurnal somnolence (n (%))  18 (36)  
Pain (n (%))  12 (24)  
Drooling (n (%))  35 (70)  
Abbreviations: PD, Parkinson’s disease; UPDRS, Unified Parkinson’s disease Rating Scale; ADL, activities 
of daily living; S&E, Schwab and England scale. a Scored during on period; b Higher numbers indicate a 
greater severity of impairment; c Higher numbers indicate more independency in the activities of daily living; 
d We were able to measure arterial blood pressure in 18 patients; MMSE, Mini Mental State Examination; 
BDI, Beck Depression Inventory 
 
Handicap 
LHS values followed a Gaussian distribution with a mean LHS total score of 0.338 (SD ± 
0.155) (Table 3). The most affected domain was Orientation.   
In simple linear regression analysis, the following variables were significantly correlated 
with the total LHS score: dementia (DSM-IV) (p < 0.001); depression (DSM-IV)  (p < 0.05); 
unsteadiness causing severe or extreme impact on patients’ perceived HS  (p < 0.05); falls 
causing severe or extreme impact on patients’ perceived HS (p < 0.05); hallucinations (p < 
0.05); H&Y in on (p < 0.01); H&Y in off (p < 0.005); patients’ residency (p < 0.05); UPDRS 
part I score (p < 0.01); UPDRS part II score in on (p < 0.01) and off (p < 0.05); S&E score in 
on (p < 0.001) and off (p < 0.01); and wearing-off (p < 0.05). Dementia (DSM-IV) was not 
correlated with UPDRS part I. 
In multiple linear regression analysis using backwards method, the independent variables 
that still remained significant were dementia (DSM-IV), UPDRS part I score, H&Y stage in 
off, S&E score in on, wearing-off and falls. The variables that best predicted the total 
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score of LHS in the final model were presence of dementia (DSM-IV) (r = - 0.66; p < 0.000), 
UPDRS part I score (r = - 0.57; p < 0.000) and H&Y stage in off (r = - 0.47; p = 0.001) (Table 
4). This model explained 62% of the variance in the total score of LHS (p = 0.000). The 
Durbin-Watson test and collinearity statistics showed lack of correlation and 
multicollinearity between the independent variables.    
 
Table 3. Total and sub-scores in the 6 domains of London Handicap Scale in Late-Stage PD patients  
 Total Mobility Physical 
independence 
Occupation Social 
integration 
Orientation Economic 
self-
sufficiency 
Mean (SD) 0.338 
(0.155) 
-0.042 
(0.044) 
-0.057 (0.003) -0.047 
(0,051) 
0.007 
(0,031) 
0.004 
(0.074) 
0.013 
(0.062) 
Median 0.325 -0.036 -0.057 -0.035 0.007 -0.008 0.033 
Minimum / 
maximum 
0.044 / 
0.628 
-0.108 / 
0.038 
-0.061 / -
0.053 
-0.350 / 
0.099 
-0.041 / 
0.063 
-0.075 / 
0.109 
-0.111 / 
0.100 
Minimum / 
maximum 
possible 
values for 
total score 
a
 
and each 
domain 
sub-score 
b
 
0 / 1  -0.108 / 
0.071  
  
-0.061 / 0.102 -0.060 / 
0.099  
-0.041 / 
0.063  
-0.075 / 
0.109  
-0.111 / 
0.100   
Abbreviations: PD, Parkinson’s disease; SD, standard deviation; 
a
 In the London Handicap Scale total score, 
0 indicates total disability and 1 indicates normal function; 
b
 In the London Handicap Scale sub-scores of the 
6 domains, the minimum value indicates most severe disadvantage and the maximum value indicates no 
disadvantage. 
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Table 4. Multiple linear regression model for London Handicap Scale  
Independent 
variables  
Unstandardized  
Beta 
Standardized 
Beta 
SE 95% CI P  Dependent 
variable  
R  R
2
  Adjust
ed R
2
  
P  
Presence of 
dementia 
(DSM-IV)  
  
 
Score in 
UPDRS 
 Part I 
 
 
Hoehn & 
Yahr staging 
in off  
 
- 0.125 
 
 
 
 
 
- 0.015 
 
 
 
 
 
- 0.115 
- 0.408 
 
 
 
 
 
- 0.368 
 
 
 
 
 
-  0.361 
0.037 
 
 
 
 
0.005 
 
 
 
 
0.034 
- 0.200; - 0.051 
 
 
 
 
 
-  0.024;  - 0.005 
 
 
 
 
 
-  0.183;  - 0.046 
0.02 
 
 
 
 
0.03 
 
 
 
 
0.02 
Total score 
in London 
Handicap 
Scale 
0.8 0.65 0.62 0.000 
Abbreviations: PD, Parkinson’s disease; UPDRS, Unified Parkinson’s disease Rating Scale; SE, standard error 
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Co-morbidities and past medical conditions 
Thirty-seven patients (74%) had co-morbidities while 27 (54%) reported past medical 
conditions (Table 5). We found no significant differences in the mean total score of LHS 
between patients with and without past or concomitant medical diseases, or those with > 
2 past or concomitant medical diseases. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PD, Parkinson’s disease. 
Table 5. Co-morbidities and past medical conditions in late-stage PD patients 
 PD patients (n = 50)  
Co-morbidities (n (%))  37 (74) 
Musculoskeletal diseases (n (%))  20 (40) 
Cardiovascular disease (n (%))  14 (28) 
Benign prostate hypertrophy (n (%))  8 (16) 
Eye cataract (n (%))  7 (14) 
Weight loss (n (%))  7 (14) 
Skin infection or ulceration (n (%))  5 (10) 
Gastrostomy (n (%))  5 (10) 
Non-skin Cancer (n (%))  3 (6) 
Skin neoplasm (n (%))  3 (6) 
Miscellaneous (n (%))  7 (14) 
Past diseases (n (%))  27 (54) 
Bone fractures in the previous 5 years (n (%))  10 (20)  
Pneumonia in the previous 5 years (n (%))  10 (20) 
Lower urinary tract infection in the previous year 
(n (%))  
10 (20) 
Kidney or bladder disease (urinary infection 
apart) (n (%))  
3 (6) 
Stroke (ischemic or hemorrhagic) (n (%))  2 (4) 
Skin neoplasm (n (%))  1 (2) 
Pulmonary embolism (n (%))  1 (2) 
Lung disease (pneumonia and embolism apart) (n 
(%))  
1 (2) 
Miscellaneous (n (%))  6 (12) 
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Use of health resources   
Most patients lived in their home and the majority had an informal caregiver. Patients 
seldom visited doctors, as the number of visits included those to get prescriptions only, 
and the use of other health resources was low (Table 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PD, Parkinson’s disease; SD, standard deviation 
 
 
 
 
Table 6. Use of health resources in late-stage PD patients 
 
 
PD patients (n = 50) 
Patients living in their home (n (%))  35 (70)  
Patients living in their relatives’ home (n (%))  7(14)  
Patients living in a nursery home (n (%))  8 (16) 
Patients with an informal caregiver (n (%))  45 (90) 
Patients with a paid caregiver (n (%)) 19 (38) 
Patients with both informal and paid caregiver (n (%))  14 (28) 
Patients visited at State-owned hospitals (n (%)) 43 (86) 
Patients visited at private clinics (n (%)) 3 (6)  
Patients visited at State-owned hospitals & private clinics 4 (8) 
Visits to family physician in the preceding 6 months (includes visits to 
get prescription only) (mean (SD))  
2.2 (3.0) 
Visits to neurologist in the preceding 6 months (includes visits to get 
prescription only) (mean (SD))  
1.7 (1.0) 
Hospital admissions in the preceding 12 months (mean (SD))  0.78 (1.0) 
Patients using a physiotherapist (n (%)) 10 (20)  
Patients using a speech therapist (n (%)) 3 (6) 
Patients using a homecare nurse (n (%)) 3 (6) 
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Caregivers 
Mean time per week spent in informal caregiving was 5 days (SD±2.57), this meaning 5 
days x 24 hours/week. Informal caregivers rated the impact of PD in their life as high 
(mean score 3.5; SD±0.8), which was significantly correlated with the LHS total score (r = - 
0.5; p < 0.01). The domains of LHS that resulted in a statistical significant association with 
caregiver burden were “Mobility” (r = - 0.30) and “Orientation” (r = - 0.4)( p < 0.05). 
DISCUSSION 
Handicap was assessed in a cohort of LS-PD patients and it was found that the LHS was 
useful and easy to apply in these patients. This cohort of LS-PD patients was highly 
handicapped. Handicap was strongly associated with the presence of dementia (DSM-IV), 
the severity of mental problems and the severity of parkinsonism in off. These 
independent variables explained more than half of the variance in the LHS total score. 
Furthermore, these patients were highly dependent on caregivers who spent much time 
in care, which resulted in a high burden for caregivers. Overall, health resources were 
used infrequently. 
Handicap 
Data about the health burden of PD obtained from patients’ perspective are essential to 
understand the impact of disease on patients, complement the data obtained through 
observer-based instruments and are useful also to assess the effectiveness of therapeutic 
interventions. The most commonly used subjective outcome measures in PD research 
have been the perceived HS, generic QoL scales and the health-related QoL (HRQoL).101 
We have explored the concept of handicap for several reasons:125,129 handicap is the 
central aim of rehabilitation,128 which is crucial in progressive and chronic diseases as PD; 
although intimately related to the concept of (HR)QoL, its definition is more objective 
though keeping the subjective perspective and social interaction context as (HR)QoL does; 
it is a focused and concrete concept, easily understandable to patients and caregivers; it 
is a relevant outcome despite being mostly limited to the context of health experience. 
Besides, there is good transcultural agreement on the construct of handicap133 and the 
objectivity of the concept allows caregivers to fill in the questionnaires in those cases 
where patients are incapable to do so. In our study, LHS was easily completed by patients 
and caregivers. The scores had a normal distribution and no ceiling or floor effects. 
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Dementia (DSM-IV), the severity of mental problems assessed by UPDRS part I108,112 and 
the severity of parkinsonism in off according to the H&Y explained a major percentage of 
the variance in the total LHS score. The H&Y staging is deeply anchored on postural 
instability, but it also reflects severity of bilateral parkinsonism.82 Indeed, others have also 
found that postural instability is among the most disabling problems in advanced PD.56-58, 
105,134 We previously reported severe disability in these same patients using observed-
based outcome measures119 and also assessed perceived HS. Results showed that falls 
and dysautonomia were the symptoms most contributing to poor perceived HS, closely 
followed by bradykinesia, freezing, bulbar symptoms, dementia (DSM-IV), apathy, anxiety 
and depression (DSM-IV).119 Interestingly, the symptoms most associated with handicap 
did not fully overlap those most impacting on the HS, suggesting that handicap and HS are 
different constructs for patients’ perception of health states. During the revision process 
that led to the new WHO International Classification of Functioning, Disability and 
Health,135 the term handicap was replaced for participation restriction, in order to move 
the emphasis from consequence of disease to functioning, health and limitation of 
functioning. Nevertheless, the major concept that one’s environment influences the 
functioning of an individual was still embodied in International Classification of 
Functioning, Disability and Health. In fact, qualitative studies showed a strong 
transcultural agreement on six domains of participation, and these corresponded to the 
handicap dimensions;136 additionally, a study by Perenboom et al137 found that 2 
handicap scales from a pool of 11 existing generic instruments were the ones closest to 
measure solely participation.  Indeed, one of those two scales was the LHS. 
Co-morbidities and past medical conditions 
PD is associated with significant co-morbidity.138 However, this excess co-morbidity is 
largely confined to conditions associated with PD such as urinary complaints or to 
complications of PD such as bone fractures.138 Similarly, the most frequent medical 
conditions of our patients were related to or complications of PD. In contrast to other 
studies,138,139 stroke, cardiovascular disorders or diabetes were either low or absent, 
suggesting that our population may have a long survival due to the lack of potentially fatal 
medical conditions. 22% of our cohort reported pneumonia in the previous 5 years, a 
finding in accordance with data showing pneumonia as a major cause of death in 
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PD.57,138,139 The finding that neither past nor concomitant diseases were associated with a 
higher handicap strengthens the finding of the impact of PD symptoms on the level of 
handicap. 
Use of health resources 
We expected a higher percentage of institutionalized patients, in light of the high UPDRS 
score, frequent falls, dementia and hallucinations in the cohort, all strong independent 
predictors of institutionalization.68 Importantly, low income, the lack of availability of 
long-stay facilities within the health system and a family-centred organisation of Latin 
societies may combine to explain our findings. Keeping patients at home was 
accomplished at the expenses of a heavy burden of disease on caregivers and the need 
for a paid caregiver in many instances.  
Our patients consulted doctors fewer times than those in a Dutch study, where PD 
patients with ≥ 8 years of disease duration made 1.9 visits to neurologist and 1.1 to family 
physician.140 Admissions to hospital were few in our sample, taking into account the 
number of co-morbidities and the frequency of psychosis and dementia. Many of these 
acute medical events might be managed in emergency rooms which could explain the low 
rate of admissions. A minority made use of other healthcare resources such as speech 
therapist or homecare nurse, whereas 20% used a physiotherapy which is a low figure 
comparing the degree of motor involvement.140  
Caregivers 
The amount of time spent in caregiving was very high in LS-PD. Accordingly, caregivers’ 
burden and mental health status in PD has been found to correlate significantly with 
weekly hours of caregiving.141-143 Two Spanish studies found that caring for patients with 
disease duration of 7.6-10 years was permanent in 86-96.5% of the cases.141-143 Caregiver 
time is thus an hidden cost in LS-PD, and in other cultures it would mean paid caregiver 
time. Caring for LS-PD patients had a strong impact on the life of caregivers and this was 
correlated with the LHS total score, in line with others reporting an increase in caregivers’ 
burden with disease severity.141-144  
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 Shortcomings  
Our low recruitment rate perhaps indicates that there were few LS-PD cases available at 
the study centers, suggesting that patients withdraw from specialized medical care once 
they reach later stages of disease. Thus, our results may not be representative for the 
entire population of LS-PD. While we addressed the concept of handicap, we did not 
measure QoL which could have been of interest in order to compare these outcomes of 
HS. More information regarding caregivers could have been gathered but our aim was to 
obtain general data concerning caregivers’ burden.  
Conclusions 
Handicap is an important patient-centred outcome measure which is valuable to use in 
LS-PD since it provides an overall measure of patients’ HS and gives insight into several 
domains of disadvantage. The LHS proved to be easily completed and might in the future 
be explored in earlier stages of disease. Our results show that LS-PD is associated with 
high handicap and caregivers’ burden, and support the notion that cognitive and 
behavioural symptoms, with a special emphasis on dementia, and severity of 
parkinsonism in particular falls and unsteadiness, should be the focus of management in 
later stages of PD. 
 
  Later stages of Parkinson’s disease 
82 
 
  
        Handicap in Advanced stage PD 
 
 
83 
 
CHAPTER 3: Handicap in Advanced stage PD 
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ABSTRACT 
Background: There is scarce data on the level of handicap in Parkinson’s disease (PD) and 
none in advanced stage PD.  
Objective: To assess the handicap in advanced stage PD patients with disabling levodopa-
induced motor complications selected to deep brain stimulation (DBS). 
Methods: Cross-sectional study of patients recruited consecutively during evaluation for 
DBS. Handicap was measured using London Handicap Scale (LHS) (0= maximal handicap; 
1= no handicap). Disease severity was evaluated using the Hoehn & Yahr scale and the 
UPDRS/MDS-UPDRS, during off and on after a supra-maximal dose of levodopa. 
Dyskinesias were scored using the modified Abnormal Involuntary Movement Scale 
(mAIMS) and the Schwab and England Scale (S&E) was also scored in off and on.  
Results: 100 PD patients (mean age 61 (±7.6); mean disease duration 12.20 (±4.6) years) 
were included. Median score of motor MDS-UPDRS was 54 in off and 25 in on. Mean total 
LHS score was 0.56 (±0.14). Patients were handicapped in several domains with a wide 
range of severity. Physical Independence and Social Integration were the most affected 
domains. Determinants of total LHS score were MDS-UPDRS part II off (β= - 0.271; 
p=0.020), mAIMS on (β= - 0.183; p=0.042), and S&E on (β= 0.264; p=0.005) and off (β= 
0.226; p=0.020) scores (R2 =29.6%).  
Conclusions: LHS was easy to apply in advanced stage PD patients. Patients were 
moderately-to-highly handicapped and this was strongly determined by disability in ADL 
and dyskinesias. Change in handicap may be a good patient-centred outcome to assess 
efficiency of DBS.  
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INTRODUCTION 
Level of handicap in Parkinson`s disease (PD) has rarely been assessed. Previously, we 
have measured the level of handicap experienced by late stage PD (LS-PD) patients using 
the London Handicap Scale (LHS).125,130,145 We found that handicap was a valuable 
patient-centred outcome (PCO) in LS-PD and that the LHS was easily completed by 
patients and caregivers despite the presence of severe disability.145 This raised the 
question whether handicap would also be a valuable measure of the health condition and 
participation of an individual in less advanced stages of PD, such as patients with disabling 
levodopa-induced motor complications (MC). 
The World Health Organization (WHO) has recently replaced the term handicap with 
participation restriction to avoid any negative connotations associated with the term 
handicap and to emphasize that the ability of an individual to participate in everyday life 
situations is limited, not only by the effects of disease, but also contextual factors.135 
Nevertheless, the operational definition of handicap still holds true for clinical research 
since it was found that the 6 domains of participation that can be potentially affected by 
health states correspond to the 6 common dimensions of handicap.135,137 Indeed, even 
though the LHS was developed using the definition of handicap, it accurately measures 
the WHO definition of participation restriction.127,137 Furthermore, handicap is a closely 
defined and focused concept which retains the subjective perspective and social 
interaction context of quality of life (QoL), and it is easily understandable to patients and 
caregivers.125  Finally, there is good cross-cultural agreement on the construct of handicap 
allowing for comparison between different populations, and the wide use of the LHS 
allows for comparison between different disease populations.126,130,133 Reducing handicap 
is a central aim of therapeutic interventions, and a better understanding of the causes of 
handicap allows for improved adjustment of interventions and assessment of their 
effectiveness.125  
Our aim was to study the handicap in advanced stage PD, which is widely defined as PD in 
patients manifesting levodopa-induced MC.45 To enrich our sample with patients suffering 
from very disabling levodopa-induced MC, we enrolled PD patients selected to receive 
deep brain stimulation (DBS). 
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PATIENTS AND METHODS 
Objective: 
To establish the pattern and level of handicap in advanced stage PD patients with 
disabling levodopa-induced MC selected to DBS, and to identify the contributing factors. 
Design: Cross-sectional study 
Participants: 
Inclusion criteria for the study were: 1) PD patients with disabling levodopa-induced MC 
who were given DBS in our centre; 2) completion of LHS. PD was diagnosed according to 
the UK Parkinson’s Disease Society Brain Bank Criteria.146 Eligibility criteria for DBS were: 
a) PD patients with disabling levodopa-induced MC refractory to best medical therapy; b) 
age below 70 years; c) a positive motor response to a levodopa challenge test (> 33% 
improvement after the intake of patients’ usual morning levodopa equivalent dose plus 
50%- a supra-maximal dose of 150%); d) lack of postural instability and freezing of gait 
during on period; e) absence of dementia associated with PD according to a formal 
neuropsychological assessment and unstable psychiatric disorder according to a formal 
psychiatry assessment; and f) lack of significant brain changes, namely atrophy or 
concurrent brain disorders such as vascular lesions on CT and MRI scan. Participants gave 
their informed consent to participate and the study was conducted according to the 
Declaration of Helsinki. 
Participants’ assessment 
PD patients were recruited consecutively during routine evaluation for DBS from 2006 to 
April 2015, and data were collected prospectively. The results of this study pertain to the 
assessment before DBS. After the development of the new Movement Disorders Society- 
Unified Parkinson’s Disease Rating Scale147 (MDS-UPDRS), we have introduced this new 
scale in the routine assessment for DBS instead of the UPDRS.94 Thus, severity of motor 
symptoms were evaluated using the motor part (part III) of the UPDRS and more recently 
the motor part (part III) of the MDS-UPDRS, and the Hoehn & Yahr (HY) scale.42,94,147 Part 
III of the UPDRS\MDS-UPDRS and the HY staging were assessed during off period and 
after the intake of a supra-maximal dose of levodopa (see above) during the best on state. 
Off period assessment was performed at least 12 hours after the last levodopa dose, 48 
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hours after the last intake of dopamine agonists, controlled-release levodopa, selegiline 
or rasagiline and 12 hours after the last intake of entacapone. The levodopa equivalent 
daily dose (LEDD) was calculated according to reported conversions.148 Non-motor 
symptoms were assessed using Part I of UPDRS\MDS-UPDRS, and disability and 
independence in activities of daily living (ADL) were evaluated using Part II of 
UPDRS\MDS-UPDRS and the Schwab and England Scale (S&E).95 The scores of UPDRS 
parts II and III were converted to the scores of MDS-UPDRS parts II and III according to 
published formula.149 Severity of levodopa-induced MC were evaluated using part IV of 
UPDRS\MDS-UPDRS, and the severity of dyskinesias was scored using the modified 
Abnormal Involuntary Movement Scale (mAIMS) in off and on state.150 The mAIMS was 
scored during rest (mAIMS rest) and counting backwards (mAIMS count). The Mini Mental 
State Examination (MMSE) was also performed as part of the formal neuropsychological 
assessment.99 
Handicap was assessed using the LHS which consists of a self-completed questionnaire 
and it takes around 10 min to be completed.130 The questionnaire has six questions, one 
for each domain of handicap (mobility, physical independence, occupation, social 
integration, orientation and economic self-sufficiency), and each question contains six 
sentences hierarchically describing the level of handicap; for each question, the patient 
must choose the most suitable sentence. Each sentence is assigned a scale weight. The 
questionnaire comprises a matrix of scale weights which when combined give a total 
score for handicap, to which a constant value of 0.456 is added. The final score ranges 
from 0 (maximal handicap) to 1 (no handicap).  
Statistical analysis 
Data analysis was performed with R software (version 2.13). A descriptive analysis was 
performed and the results expressed as mean ± standard deviation or percentages. The 
total score of the LHS was entered as a dependent variable in linear regression analysis. 
Multiple linear regression analysis, adjusted for age and gender, was performed to 
calculate which variables contributed significantly to higher levels of handicap (the lower 
the total score of the LHS the higher the level of handicap). The following independent 
variables were entered: gender, duration of the disease, scores of the MDS-UPDRS part II 
on and off and MDS-UPDRS part III on and off, HY stage on and off, S&E score on and off, 
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scores of mAIMS rest on and off and mAIMS count on and off, and the LEDD. We used 
both-stepwise regression to select significant variables from the original model. Statistical 
significance was considered for p < 0.05. Coefficients and 95% confidence intervals (CIs) 
are reported. 
RESULTS 
One-hundred sixty-six patients were given DBS at our centre from 2006 to April 2015. 
Missing entries in the LHS of 66 patients precluded the inclusion of those patients in the 
analysis, thus LHS data from 100 patients (63 males) were available to analysis. There 
were no significant differences between demographic or clinical data of patients included 
and not included in the study (data not shown). At the time of surgery, mean age of 
patients was 61 (±7.6) years and mean disease duration was 12.20 (±4.6) years (Table 1).  
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Table 1: Demographic and clinical characteristics of advanced PD patients (n = 100) 
Demographics 
 
Mean (SD)/Median(min-max) 
Age, years 61 (7.6) 
disease duration, years 12.20 (4.6) 
Gender: male (n(%)) 63 (63.6%) 
Clinical Characteristics 
Response in levodopa challenge test,% 57.89 (14.83) 
MDS-UPDRS I (n=43) 5 (0-29) 
MDS-UPDRS II on 15 (0-30) 
MDS-UPDRS II off 22 (5-41) 
MDS-UPDRS III on  25 (3-48) 
MDS-UPDRS III off  54 (26-95) 
MDS-UPDRS IV (n=43) 9.50 (0-18) 
UPDRS I (n=57) 3 (0-6) 
UPDRS IV (n=57) 8 (0-20) 
S&E on 90 (0-100) 
S&E off 50 (0-100) 
HY on 2 (0-4) 
HY off 2.50 (0-5) 
mAIMS rest off 0 (0-10) 
mAIMS count off  0 (0-11) 
mAIMS rest on 4 (0-17) 
mAIMS count on 8 (0-21) 
MMSE 28 (22-30) 
 
As parts I and IV of UPDRS are not converted to MDS-UPDRS, the table indicates how many patients have 
completed parts I and IV of UPDRS and parts I and IV of MDS-UPDRS  
Abbreviations: PD, Parkinson’s disease; (MDS)-UPDRS, (Movement Disorders Society)-Unified 
Parkinson’s disease Rating Scale; S&E, Schwab and England scale; HY, Hoehn and Yahr; mAIMS, modified 
Abnormal Involuntary Movement Scale; MMSE, Mini Mental State Examination; SD, standard deviation 
 
LHS values followed a Gaussian distribution, with a median total score of 0.509 (0.21-
1.00) and a mean of 0.56 (±0.14) (Table 2). No ceiling or floor effects were noted. Female 
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and male patients were equally handicapped. There was a wide range of responses 
between the different levels of disadvantage for each domain of handicap, which 
indicated that the LHS could discriminate well between patients. However, the most 
common categories within each domain of the LHS were “quite a lot” and “very slightly” 
disadvantage, with fewer subjects scoring in the “almost completely” and “completely” 
disadvantage categories. DBS patients were handicapped over several domains of the 
LHS. The domains for which more patients scored a greater disadvantage (“very much”, 
“almost completely” and “completely”) were Economic Self-sufficiency (n=26), 
Occupation (n=25) and Mobility (n=10). The Physical Independence sub-score (r = 0.777, p 
< 0.001) and the Social Integration sub-score (r = 0.657, p < 0.001) showed the greatest 
association with the LHS total score, thus these were the most severely affected domains, 
closely followed by the Mobility sub-score (r = 0.634, p < 0.001). In multiple linear 
regression analysis, using the LHS total score as the dependent variable, 2 models were 
the most informative. In model 1, the independent variables that were most associated 
with handicap were the scores of MDS-UPDRS part II off (β = - 0.271; p = 0.020), mAIMS 
count on (β = - 0.183; p = 0.042), and S&E on (β = 0.264; p = 0.005) and off (β = 0.226; p = 
0.020) (Table 3). This model R2 was 29.6%. In model 2, the LEDD variable was replaced by 
the dose of each antiparkinsonian drug used in our population and the presence/absence 
of dopamine agonists. The dose of entacapone came out significant in model 2 (β = - 
0.223; p = 0.014), but a R2 of only 1.4 was gained (31%). 
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Table 2: Total and sub-scores of London Handicap Scale and correlations with total  scores 
 
 
Mean (SD) 
Median  
(Min,max) 
Minimum / 
Maximum 
possible values 
for total score 
and sub-score
 
Pearson 
correlati
on with 
total 
score 
p-value 
for 
correlati
on 
Social Integration 0.021 (0.028) 0.035 (-0.029, 0.630) -0.041 / 0.063 0.657 <0.001 
Orientation  0.055 (0.064) -0.109 (-0.063, 0.109) -0.075 / 0.109 0.473 
<0.001 
Economic self 
sufficiency 
0.035 (0.043) 0.033 (-0.111, 0.100) -0.111 / 0.100 0.522 <0.001 
Mobility 0.019 (0.033) 0.000 (-0.036, 0.071)  -0.108 / 0.071  0.634 <0.001 
Physical Independence  0.004 (0.056) 0.011 (-0.057, 0.102) -0.061 / 0.102 0.777 <0.001 
Occupation -0.004 (0.039) -0.014 (-0.060, 0.099) -0.060 / 0.099 0.428 <0.001 
Total 0.585 (0.152) 0.567 (0.274, 1.000) 0 / 1 NA NA 
Abbreviations: SD, standard deviation; NA, not applicable 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: MDS-UPDRS, Movement Disorders Society-Unified Parkinson’s disease Rating Scale; 
mAIMS, modified Abnormal Involuntary Movement Scale; CI, confidence interval 
 
 
  
 β 
Coefficients 
95% CI for β t-test p-value 
MDS-UPDRS II off -0.271 -0.007 -0.001 -2.834 0.006 
Schwab & England on 0.264 0.001 0.004 2.902 0.005 
Schwab & England off 0.226 0.000 0.003 2.370 0.020 
mAIMS count on -0.183 -0.009 0.000 -2.066 0.042 
Table 3: Regression model for the London Handicap Scale 
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DISCUSSION 
Handicap was assessed in advanced stage PD patients with disabling levodopa-induced 
MC prior to DBS implant, using the LHS which was found to be an easy to apply tool in 
these patients. The study population was moderately-to-highly handicapped, and the 
level of handicap was strongly determined by the disability and independence in ADL, and 
the severity of peak-dose dyskinesias during the levodopa challenge test. These 
independent variables accounted for one-third of the patients’ handicap. 
We have previously reported the assessment of handicap, using the LHS, in a population 
of LS-PD patients.145 We found that handicap was a valuable PCO in LS-PD and the LHS 
was easily completed even in those very disabled patients.145 We now add findings on the 
assessment of handicap, using the LHS, in PD patients that are in a less advanced stage 
than LS-PD. We chose patients selected to DBS because they are the prototype of patients 
with disabling MC, which is the more widespread definition of advanced stage PD.45 We 
are aware though that DBS patients are a sub-group of PD patients with MC, but we 
aimed to study that pure sample of patients with MC. Additionally, we aimed to explore 
handicap and the LHS as a PCO of patients’ health condition in DBS patients to test in 
future whether it may be sensitive to change after surgery.  
The overall handicap of DBS patients was lower than that of LS-PD patients, who had a 
mean LHS total score of 0.338 (± 0.155).145 This suggests that DBS patients, although 
manifesting very disabling MC, are less handicapped than more advanced PD patients 
whose clinical picture is dominated by motor and non-motor symptoms which are poorly 
responsive to L-dopa.57,145 On the other hand, the level of handicap of DBS patients was 
greater than that reported for stroke survivors at 6 months, 2 and 5 years whose mean 
LHS score ranged from 0.73 to 0.93.151-153 Unfortunately, there is no data regarding 
handicap in other neurodegenerative disorders to compare with, such as Alzheimer’s 
disease or amyotrophic lateral sclerosis. The Physical Independence and Social Integration 
domains were the most severely affected in our patients. Disadvantage in Physical 
Independence reflects an inability to look after oneself in tasks such as housework, 
shopping, looking after money, getting dressed and using the toilet, while disadvantage in 
Social Integration reflects an inability to meet family, friends and other people during a 
normal day.130 Our results show that patients with disabling MC are highly handicapped 
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when it comes to looking after themselves independently and conducting a healthy social 
life. Due to the surgery criteria, patients selected to DBS could not have dementia, which 
may explain why Orientation was not a severely affected domain, when this was the most 
handicapped domain seen with LS-PD patients who had a high frequency of dementia.145 
It seems that LS-PD patients are a particular and distinct sub-group of advanced stage 
PD.145 DBS patients also differ from stroke survivors who are most affected in domains 
that are more motor dependent (Mobility, Physical Independence and Occupation).152,153  
Factors associated with greater handicap were the disability and independence in ADL 
(MDS-UPDRS part II and the S&E scale) and the severity of peak-dose dyskinesias. This 
reflects how motor impairment impacts on ADL in this sample of DBS patients and why 
Physical Independence and Social Integration were the most affected domains of LHS. 
Interestingly, the score of MDS-UPDRS part II in off but not on was correlated with level of 
handicap, suggesting that the severity of disability when patients are in off period may 
better translate the severity of PD. Also of interest, neither the MDS-UPDRS motor part 
nor the response to levodopa or the LEDD correlated with level of handicap, probably 
because they were very homogeneous between patients. However, peak-dose 
dyskinesias predicted greater handicap in DBS patients. Indeed, they are a major 
indication for DBS because of the disability they cause.81,154 Unexpectedly, parts IV (motor 
complications) of UPDRS and MDS-UPDRS were not significantly associated with the LHS, 
probably due to the small sample size of patients completing either the UPDRS or the 
MDS-UPDRS as the scores of UPDRS part IV are not possible to convert to MDS-UPDRS.149 
However, it may also suggest that dyskinesias should be scored during the levodopa 
challenge test when selecting patients for DBS. Additionally, LHS score was not predicted 
by part I (non-motor symptoms) of UPDRS/MDS-UPDRS, which may be related to the 
absence of dementia, psychosis or unstable psychiatric disorders in patients selected for 
DBS or, alternatively, due to small sample size as mentioned above for part IV of 
UPDRS\MDS-UPDRS. 
QoL and health-related QoL ((HR)QoL), a concept intimately related to, but distinct from, 
handicap, is similarly poor in PD patients with MC.40,47,48,125,155,156 Data suggest that motor 
fluctuations might have a stronger impact than dyskinesias on HR(QoL), and that the level 
of disability associated with dyskinesias might vary according to severity of PD.47,48,155,156 
However, (HR)QoL scales are not very sensitivity to change in disease progression over 
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time in PD.157 Handicap might thus be an alternative candidate as a PCO to measure 
change after DBS. Additionally, handicap is a concept easily understood by patients and 
caregivers, and more closely defined and focused than QoL.125  
Our study has some limitations. If all patients had completed either the UPDRS or the 
MDS-UPDRS, the study would have more power to test the contribution of parts I and IV 
of these scales to the level handicap of patients. We did not enrolled patients with 
disabling MC that were excluded from DBS after assessment. In these patients, the 
severity of handicap and its contributors might have differed from the patients we 
included. Finally, it would have been interesting to use a (HR)QoL scale to assess our 
patients, to permit a head-to-head comparison between handicap and (HR)QoL ratings. 
This would be particularly interesting when assessing the responsiveness of handicap 
scales to DBS. 
In conclusion, we were able to use handicap to measure overall health condition and 
individual’s participation in advanced PD patients with disabling levodopa-induced MC 
selected to DBS. The LHS was easily completed by patients and we have now values for 
the LHS in advanced and late-stage PD patients. Further studies are now needed to assess 
how sensitive the LHS is to measure changes in handicap after DBS.  
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CHAPTER 4: Concept and a proposal for a definition of Late-Stage PD 
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ABSTRACT 
The cardinal symptoms of Parkinson’s disease (PD) are asymmetrical bradykinesia, 
rigidity, resting tremor and postural instability. However, the presence and spectrum of, 
and disability caused by, non-motor symptoms (NMS) are being increasingly recognized. 
NMS include dementia, psychosis, depression and apathy, and are a major source of 
disability in later stages of PD, in association with axial symptoms that are resistant to 
levodopa therapy. The model of clinical progression of PD should, therefore, incorporate 
NMS, instead of being restricted to motor signs and levodopa-induced motor 
complications. Patients with disabling motor complications are classified as having 
advanced PD, which has been thought to represent the ultimate stage of disease. 
However, deep brain stimulation to treat motor complications has dramatically changed 
this scenario, with implications for the definition of advanced stage disease. As treatment 
improves and survival times increase, patients are increasingly progressing to a later 
phase of disease in which they are highly dependent on caregivers, and disability is 
dominated by motor symptoms and NMS that are resistant to levodopa. In this article, we 
review the changing landscape of the later stages of PD, and propose a definition of late-
stage PD to designate patients who have progressed beyond the advanced stage.   
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INTRODUCTION 
Parkinson’s disease (PD) is the second most common age-related neurodegenerative 
disorder after Alzheimer disease. PD occurs worldwide with an age-adjusted prevalence 
of 1.8% and similar incidences in females and males.29 The mean age of onset is about 65 
years, with prevalence rising from 0.6% at age 65–69 years to 2.6–3.5% at age 85–89 
years.29-30 Disability in this disease is progressive158 and associated with increased 
mortality (relative risk of death 1.6–3.0 compared with matched control populations).8, 31 
The primary pathology of PD is progressive dopaminergic neuronal loss in the substantia 
nigra, but other neurotransmitter systems (cholinergic, noradrenergic and serotonergic) 
are also affected.9,10 Clinically, PD is characterized by the motor symptoms of 
asymmetrical bradykinesia, rigidity and rest tremor, as well as postural instability later in 
the disease course.33 However, non-motor symptoms (NMS) such as dementia, 
depression, pain, sleep disorders and dysautonomia increase in frequency and severity in 
later disease stages.34 The available pharmacological and surgical treatments substantially 
improve motor symptoms, but achievement of satisfactory symptomatic control becomes 
difficult in more-advanced disease stages. Levodopa remains the most potent 
antiparkinsonian drug, but its long-term use is associated with development of motor 
complications.35,40  
This Review discusses data regarding the phenotype of later stages of PD, including the 
widely accepted advanced stage PD, which features motor complications, and the less-
well characterized subsequent stages, which feature disability ‘milestones’ in the 
approximately 5 years preceding death. We focus on the changing landscape of later 
stages of PD over the past decade, and discuss the emerging concept of late-stage PD. 
Such aspects of PD are becoming increasingly relevant as neurologists are more often 
treating patients with very-advanced stage PD owing to improved treatment and 
increased survival. 
PROGRESSION OF PD  
Traditionally, progression of PD is regarded as an increase in severity of motor 
symptoms—which can be either levodopa-responsive or levodopa-resistant54,55 —
together with the emergence of levodopa-induced motor complications.39 This motor 
progression is nonlinear, with a more rapid decline in motor function in earlier stages 
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compared with later stages.55,159 A recent study found that an increase of 2.5 points in the 
motor Unified Parkinson Disease Rating Scale (UPDRS) score,94 or of 4.3 points in the total 
UPDRS score, is the minimum change required to be recognized by patients as being 
clinically significant.160 
Motor complications  
Most patients with PD who receive dopaminergic therapy go on to develop motor 
complications.50,161 The frequency of this phenomenon varies among studies, but seems 
to affect about 40–50% of patients after 4–6 years of levodopa treatment.39 Occurrence 
of motor complications is most strongly related to disease duration, and to duration and 
dose of levodopa treatment.39,155 However, in the ELLDOPA trial, a substantial number of 
patients developed motor complications within 9 months of levodopa treatment.87 In 
advanced stages of PD, motor complications have a considerable impact on quality of life 
(QoL) and patient disability.40,47 The domains of QoL that are most affected seem to be 
mobility, activities of daily living (ADL), stigma and communication.40 Interestingly, in 
patients with disease duration of 5–10 years, a higher levodopa dose was associated with 
better QoL despite an increased prevalence of motor complications.155 Compared with 
the general population, PD patients with motor complications had a worse QoL, which 
deteriorated substantially with disease severity.162 However, in later disease stages, 
disability from motor complications seemed to decline relative to disability associated 
with symptoms that are resistant to levodopa.56,57,119 Some studies even found that 
motor complications remitted in some patients59,119—a finding that did not correlate with 
a reduction in the dose of antiparkinsonian drugs. 
Levodopa-resistant symptoms  
The clinical progression of PD in later stages is increasingly recognized to be dominated by 
the emergence or aggravation of symptoms that are nonresponsive to levo-
dopa.56,57,65,90,163,164 These can include NMS such as dementia, psychosis or dysautonomia, 
and axial motor symptoms such as falls, postural instability or dysphagia. These 
symptoms are the main determinants of QoL, and are a major source of disability, as well 
as being risk factors for institutionalization and death.56,57,59,65,119,163-166 As such, NMS and 
axial motor symptoms that are resistant to levodopa should be incorporated into the 
classic model of PD progression.  
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Sequence of events  
Some motor symptoms and NMS tend to progress together, and a study found that a 
cluster of variables consisting of NMS (cognitive impairment, psychosis, depression, 
daytime sleepiness, autonomic dysfunction) and axial symptoms was strongly associated 
with disease progression.134 These findings suggest that, together, NMS and axial 
symptoms dominate the clinical picture of late stages of PD, and that they share common 
pathogenic mechanisms. Intuitively, one thinks that PD starts with prodromal 
symptoms,167 followed by unilateral and then bilateral motor symptoms, progressing to 
motor complications, balance and gait impairments, and finally psychosis and 
dementia.1,57 This sequence of events is not, however, a universal rule, although we 
cannot yet predict with much certainty which patients will, for example, develop 
dementia before motor complications. 
STAGING OF PD  
For several decades, attempts have been made to stage the clinical evolution of PD.42 In 
the pre-levodopa era, Hoehn and Yahr developed a staging system to describe clinical 
function at different stages of disease, including the concepts of disability (functional 
deficits) and impairment (objective signs).42,82 The Hoehn and Yahr scale was based on the 
concept that the severity of parkinsonism depended mainly on the presence of bilateral 
symptoms and compromise of gait and balance, and that physical independence was 
ultimately lost owing to postural instability, gait disorder and severe bilateral 
parkinsonism.42,82 This scale has been the most widely used tool to stage the severity of 
parkinsonism,83 and available data show significant correlations between later Hoehn and 
Yahr stages and worse scores for QoL and motor impairment.85,86  
In addition to physical signs, the Hoehn and Yahr scale can capture other important 
features of PD: when patients reach stage 3, risk of dementia is increased and survival 
decreases, and total UPDRS scores increase despite drug adjustment.82,84 Advanced PD is 
commonly defined as stages 4 and 5 on the Hoehn and Yahr scale, which corresponds 
with loss of physical independence.82  
Some weaknesses of the Hoehn and Yahr scale can bias its use. First, incorporation of two 
indices of severity —impairment and disability—can create ambiguity and difficulty in 
classifying individual patients, as these indices do not necessarily progress in parallel and 
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may even diverge. Second, the indices are particularly sensitive to postural instability and 
disorders of lower limbs, thereby increasing the likelihood of overlooking disease 
progression that is attributable to other motor symptoms or NMS. Last, the Hoehn and 
Yahr scale broadly categorizes rather than finely grading disease stages, such that an 
increase in stage does not necessarily entail an overall increase in the patient’s motor 
dysfunction in all cases. As such, patients of different impairment severity can be assigned 
to the same stage of the Hoehn and Yahr scale, creating clinical heterogeneity in each 
category.82  
Overall—and despite its weaknesses—the Hoehn and Yahr scale remains the most robust 
staging system for PD. Nevertheless, in order to capture the multidimensional causes of 
disability in later stages of PD, criteria other than the Hoehn and Yahr scale might be 
needed to define such disease stages, as discussed below.  
As an alternative to the Hoehn and Yahr scale, the definition of advanced stage PD has 
rested on the presence of motor complications, as their occurrence increases with 
disease duration and severity, and they are a major source of disability.40,51,168 In this 
staging system, patients are usually classified as having advanced stage disease once 
motor complications begin,59 or when these symptoms become severe enough to 
substantially impair QoL and independence in ADL.45 A different definition of advanced 
stage PD was recently proposed,169 which encompasses patients manifesting the cardinal 
motor symptoms of PD, together with disease-related or drug-induced motor and non-
motor complications. This definition has the advantage of combining disease-related and 
drug-related symptoms with motor symptoms and NMS in the criteria for advanced PD. 
ADVANCED-STAGE PD: A MOVING CONCEPT  
The advent of deep brain stimulation (DBS) has radically advanced the treatment of 
motor complications and, therefore, the phenotype and natural history of advanced PD.74, 
170  
DBS is a powerful therapeutic intervention for advanced PD, leading to substantial 
reductions in motor symptoms and motor complications, doses of antiparkinsonian drugs, 
and disability.74,75,88 DBS also increases QoL of patients with PD171-173 and, more recently, 
was found to be superior to best medical therapy for the treatment of motor 
complications.75,173,174 This motor improvement is sustained overall at 10 years after DBS 
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of the subthalamic nucleus, with the exception of axial signs, which progressively worsen 
over time.76 
DBS is neither curative nor neuroprotective, and cannot, therefore, arrest 
neurodegeneration and clinical progression. In the long term, patients who have received 
DBS deteriorate owing to axial, cognitive, and behavioural symptoms that are not 
responsive to treatment.74,76, 88  
ADVANCED STAGE VERSUS LATE-STAGE PD  
Heterogeneity in advanced stage PD  
The classic concept of advanced stage PD is broad and, depending on the definition used, 
encompasses patients with bilateral disease, postural instability and physical dependence 
(according to Hoehn and Yahr staging) and/or patients with motor complications. 
Considerable heterogeneity exists among patients with advanced stage disease, owing to 
variations in the predominance and severity of motor symptoms and NMS, and in the 
presence and severity of motor complications, as well as the possible use of DBS.  
Disease duration is thought to be a key determinant of the stage of progression, but 
baseline characteristics of patients with advanced PD who were enrolled in clinical trials 
for motor complications and PD-associated dementia (Table 1) suggest the involvement 
of other factors and considerable heterogeneity between patients at this stage of 
disease.75,173-176 These data also highlight the fact that the sequence of events is not 
universal for all patients and that a subset of patients categorized under the term 
‘advanced disease’ do not fulfil the usual definition of advanced PD. More-nuanced 
definitions of the late stages of PD are, therefore, needed. 
  
  Later stages of Parkinson’s disease 
108 
 
 Table 1  Baseline features of patients in trials for drug-induced MC and PD-associated dementia  
Parameter  Clinical 
trial of 
drugs for 
MC  
 Clinical trials of deep brain stimulation for MC   Clinical trials for PD-associated dementia  
Rascol 
 et al. 
(2005)175 
 Deuschl et al. 
(2006)75 
Weaver et al. 
(2009)174 
Williams et al. 
(2010)173 
 Aarsland et al. 
(2009)177 
Leroi et al. 
(2009)178 
Emre et al. 
(2004)179  
Emre et al. 
(2010)176 
Mean age at PD 
onset (years)  
55.0  47.0 50.0 47.6 69.5 65.9 63.0 65.5 
Mean age 
(years)  
64.0  60.5 62.3 59.0 76.5 75.7 72.0 72.5 
Mean disease 
duration (years)  
9.0  13.5 12.4 11.4 7.0 9.75 9.0 7.0 
UPDRS motor 
score during 
‘on’ time  
23.6  18.0 23.0 19.5 11.2* 24.2 34.0 30.0 
Mean levodopa 
treatment 
duration (years)  
7.5  13.5 11.7‡ NA NA NA NA NA 
 *Modified motor UPDRS, score range 0–32. ‡Anti-PD drugs, not necessarily levodopa. Abbreviations: MC, motor complications; NA, not available; 
PD, Parkinson disease; UPDRS, Unified Parkinson Disease Rating Scale.  
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The concept of late-stage PD  
Evidence suggests that at least a small subset of patients with advanced stage PD will 
progress to a later phase of disease (Figure 1). In this latter stage, disability from motor 
complications is reduced, because these complications attenuate either naturally or in 
response to DBS.57 Disability in the later stage is dominated by levodopa-resistant motor 
symptoms and NMS,56,180,181 so that patients no longer fit the classic definition of 
advanced stage disease, which is characterized by disabling motor complications. Patients 
with late-stage PD present with a distinct phenotype, which seems more homogeneous 
than that denoted by the generic name of advanced stage disease. They require specialist 
medical care,56 although they are usually excluded from clinical trials and even from 
observational studies.  
On the basis of our research in patients who progress beyond advanced PD,119 we 
propose the term ‘late-stage’ to describe patients who are highly dependent on 
caregivers for ADL, owing to treatment-resistant motor symptoms or NMS. For this 
definition, we use the Schwab and England ADL Scale,95 which is a questionnaire that 
measures patients’ perceived functional independence. Scoring ranges from 0% (denoting 
a bedridden or vegetative state) to 100% (denoting normal ability with complete 
independence), with 10% increments. The scale is easy to apply, has moderate to 
substantial validity and good reliability, and correlates well with UPDRS motor 
scores.182,183 Furthermore, the sensitivity of the Schwab and England scale tends to 
increase with higher Hoehn and Yahr stages, thus requiring smaller sample sizes to 
compare patients in more-advanced Hoehn and Yahr stages.182 
Our proposed operational definition of late-stage PD is a score on the Schwab and 
England Scale of less than 50% during periods of adequate symptom control (‘on’ period). 
A score of 50% corresponds with the patient requiring help with half of their chores and 
experiencing difficulty with all activities. A score of 40% corresponds with the patient 
being highly dependent on support from carers, able to assist with all chores, but unable 
to complete most tasks alone.95 
We are aware that the designation of ‘late-stage’ to define the ultimate phase of PD 
deserves further discussion by clinicians, researchers and patients in order for all parties 
to reach consensus on its appropriateness, understandability and utility. We think that 
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the Schwab and England Scale and a 50% threshold are suitable, but discussion and 
validation is also required. 
 
 
Figure 1. Progression of PD in the post-levodopa and deep brain stimulation era 
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Clinical phenotype of late-stage PD 
Both cross-sectional and longitudinal data show that disability in more-advanced stages 
of PD is mainly determined by motor symptoms and NMS that are resistant to 
levodopa.42,56-59,90,119,180,181,184 The severity and frequency of NMS seem to increase with 
advancing disease.56,90,164,180,181,184,185 The PRIAMO study found that from Hoehn and Yahr 
stage 1 to stage 4–5, the frequency of NMS increased in 11 NMS domains 
(gastrointestinal, urinary, pain, sleep, fatigue, apathy, attention and memory, skin 
symptoms, psychiatric, respiratory, and miscellaneous), but not in the domain of 
cardiovascular symptoms.180 For example, 43% of patients at Hoehn and Yahr stage 1 
experienced urinary symptoms, compared with 90% of those at stage 4–5. Similarly, 61% 
of patients at Hoehn and Yahr stage 1 reported psychiatric symptoms, compared with 
84% of patients at stage 4–5.180 
A study on neuropsychiatric symptoms in patients with PD also found that the severity of 
depression, dementia and psychosis increased with disease severity.181 Interestingly, this 
study found that patient age, as well as Hoehn and Yahr stage, influences disease 
severity. The types and relative frequencies of most neuropsychiatric symptoms, 
however, seem to be similar across all stages, indicating that the presence (but not the 
severity) of these symptoms is independent of staging.60,106,119 
The Sydney cohort study provided 20-year follow-up data on individuals with PD who 
were initially enrolled in a clinical trial for levodopa-naive patients.56,57 In a report of 
outcomes at 15 years,56 prevalence figures were 81% for falls, 79% for daytime 
sleepiness, 50% each for hallucinations, depression and choking, 48% for dementia, and 
41% for urinary incontinence. Among the 30 patients surviving until 20 years of follow-
up,57 falls, freezing, dementia and moderate dysarthria were each seen in over 80%, 
hallucinations, excessive daytime sleepiness and urinary incontinence were each 
experienced by more than 70%, and choking occurred in 48%. Motor complications were 
frequent at 20 years, affecting 95% of patients, but were not a major cause of 
disability.56,57 
In fact, results from several studies suggest that the severity of motor complications 
decreases as disease progresses, which could explain in part the increased importance of 
NMS in later stages of PD.56,59,105,119,186,187 We have reported comparable findings in our 
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cohort of 50 patients with PD who have a mean disease duration of 18 years.119 The 
symptoms with the greatest impact on perceived health status were falls, unsteadiness, 
urinary dysfunction and excessive sweating. 
Disability milestones in late-stage PD 
Disability milestones were defined by Kempster et al. as symptoms of disease 
advancement that are likely to require additional medical attention.105 Motor symptoms 
and NMS that are nonresponsive to levodopa are the most reliable predictors of nursing 
home placement and mortality.56,67-69,164 The strongest independent predictors of 
institutionalization and death are postural instability and falls, dementia, and 
hallucinations.56,67-69,163,164 Moreover, two clinicopathological studies showed that four 
disability milestones (visual hallucinations, falls, dementia and institutionalization) tend to 
cluster together in the late phase of PD and precede death by around 5 years (Figure 1, 
Table 2).105,188 This time-locked relationship between occurrence of these four disease 
milestones and death seems to be independent of age at disease onset, disease duration 
and age at death.105,188 On average, the milestones preceded death by the following time 
intervals: 5.1 years for visual hallucinations, 4.1 years for falls, 3.3 years for dementia, and 
3.3 years in the case of institutionalization.188 The main difference between patients was 
the milestone-free duration of disease. Patients with earlier disease onset had longer 
disease duration before the occurrence of milestones and death, a stronger response to 
levodopa, and more-severe motor complications, whereas patients with later disease 
onset had a shorter disease course, a weaker response to levodopa, and no motor 
fluctuations.105 Thus, a late phase of PD seems to progress in the same fashion regardless 
of the preceding disease course.105,188 
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Table 2: Parkinson disease disability milestones in selected longitudinal cohorts 
 
Variable Sydney cohort, 
15 years  
(2005)
56
 
Sydney cohort, 
20 years  
(2008)
57
 
Kempster et al. 
(2007, 2010)
105,188
 
Stavanger 
Parkinson Project 
(Norwegian 
cohort)* 
Number of 
patients 
52 30 129 230 (in the baseline 
cohort) 
Age 71 74 75.5 73.5 at baseline 
Duration of 
follow-up  
15.2 20 NA 16 (longest report) 
Visual hallucinations 
Age at onset 66.7‡ NA 70.4‡ 77.8‡ (for those with 
hallucinations) 
Time to onset 10.7 NA 8.5‡ 13.0 (for those with 
hallucinations) 
Falls 
Age at onset 67.5‡ NA 71.4‡ NA 
Time to onset 11.5 NA 9.5‡ NA 
Residential home admission 
Age at admission NA 71.6§ 72.2‡ NA 
Time to admission NA 9.6§ 10.5‡ NA 
Dementia 
Age at onset 75.2 71.6 72.2‡ 78.4 
Time to onset 15.1 10.9 10.5‡ 13.8 
Death 
Age at death 75.5 76 75.5 81.1 
Time to onset 12.2 12.4 13.7 15.8 (median) 
 
Apart from numbers of patients, all data, unless otherwise stated, represent mean values in years. *Figures 
for this table were extracted from the many reports published by the Stavanger Parkinson Project. ‡We 
calculated these values on the basis of the data provided in the original studies. §Estimated value for 
initial sample. Abbreviation: NA, not available.  
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Late-stage PD in clinical practice 
The prevalence of late-stage PD is likely to increase in the future owing to better general 
health care, increased longevity and better clinical management of PD.92 Patients at this 
stage of disease will be a heavy burden for families and healthcare systems, and 
caregivers will require specialist training. Nevertheless—and perhaps importantly—
patients tend to withdraw from specialized medical care once they reach a very advanced 
stage of PD, for reasons that remain unclear. Practising clinicians will face considerable 
challenges in managing these patients and their caregivers. 
Clinical assessment and therapeutic management of patients with late-stage PD should 
focus on such problems as falls and postural instability, urinary dysfunction, freezing, 
bradykinesia, dysarthria and choking, dementia, psychosis, excessive daytime sleepiness, 
apathy, depression and anxiety. Treatment for motor complications should be less of a 
priority (Table 3).56,59,90,119,163,180-181,184-185 Clinicians should be proactive in asking patients 
and caregivers about NMS, as these symptoms are often not declared to healthcare 
professionals.189 Differential diagnosis and rigorous ascertainment of dementia, apathy, 
depression and even psychosis is particularly difficult in this population, owing to severe 
dysarthria and daytime somnolence.56,119,180-181,185 For other symptoms, the situation is 
more clear-cut: bradykinesia is usually severe whereas rigidity is either absent or mild, 
which could assist in making a differential diagnosis;119 notably, reliance on the presence 
of rigidity could mislead judgments on the severity of parkinsonism. 
Effective treatments are lacking for most levodopa-resistant symptoms. Pharmacological 
management is further complicated by adverse effects—namely, psychosis and excessive 
daytime sleepiness—induced by antiparkinsonian drugs. Management strategies should 
aim for regimen simplification, focusing on problematic symptoms for which efficacious 
treatments are available. For example, in our study of 50 patients with late-stage PD, 
levodopa was taken as monotherapy in 36% of patients, and 50% were taking 
neuroleptics, mainly clozapine.119 
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Table 3: Frequency of drug-induced motor complications and nonmotor symptoms in selected studies 
Variable 
Coelho et al. 
(2010)
119
 
Sydney 
cohort,  
15 years 
(2005)
56
 
Sydney 
cohort,  
20 years 
(2008)
57
 
Kempster et al. 
(2010)75
188
 
Kempster et al. 
(2007)
105
 
Papapetropo
ulos et al. 
(2005)
90
 
Stavanger 
Parkinson 
Project* 
Katzenschlager 
et al. 
 (2008)
190
 
Motor 
fluctuations 
39 (78) 50 (96) 30 (100) NA 62 (64.0) 32 (47.8) 53 (22.1) at 
9.1 years of 
PD duration 
56 (53.3) 
Dyskinesias 31 (62) 49 (94) 30 (100) NA 60 (61.8) 28 (41.8) NA 59 (56.2) 
Troublesome or 
moderate–
severe 
dyskinesias 
13 (26) 6 (12) 3 (10) NA NA NA NA 38 (36.2) 
Dementia 25 (50) 25 (48) 25 (83) 70 (54) with 
cognitive 
disability 
54 (55.6) with 
cognitive 
disability 
34 (50.7) 21 (46.6) of 
those 
evaluated at 
12 years 
27 (24.7) 
Falls 25 (50) 41 (81) 27 (87) 45 (35) 32 (33.0) 39 (58.2) NA NA 
Visual 
hallucinations 
22 (44) 26 (50) 23 (74) 77 (61) 57 (58.7) 35 (52.2) 12 (48.0) of 
those 
evaluated at 
12 years 
NA 
Depression 31 (62) 22 (54% of 
those tested) 
15 (50) on 
antidepressant 
NA NA 29 (43.3) 19 (24.0) at 
17.0 years of 
PD duration 
NA 
Urinary 
dysfunction 
32 (64) 22 (41) 22 (71) NA NA 19 (28.4) had 
autonomic 
dysfunction 
n/a NA 
Daytime 
sleepiness 
18 (36) 41 (79) 21 (70) NA NA NA 40 (45.0) at 
16.8 years of 
PD duration 
NA 
Dysphagia 34 (68) “Common” 15 (50) had 
choking 
NA NA NA n/a NA 
Mean UPDRS 
motor score  
(SD) 
49.2 (13) 41.2 (SD NA) NA NA NA NA 47.1 (20.7) at 
16.8 years of 
PD duration 
NA 
Apart from UPDRS motor scores, values shown in the table refer to numbers of patients, and values in brackets express the number of patients as a percentage of the total number of 
patients in the cohort. *Figures for this table were extracted from the many reports published by the Stavanger Parkinson Project. Abbreviations: NA, not available or not applicable; 
UPDRS, Unified Parkinson Disease Rating Scale.  
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Late-stage PD in clinical research 
The phenotype of PD changes considerably in later stages, and the symptoms that 
contribute most to disability in later stages differ from those in less-advanced and early 
stages.56,59,90,119,163,180,181,184,185 These changes probably reflect the dynamics of 
neurodegeneration over time, together with the effects of antiparkinsonian drugs.1-2 In 
this sense, late-stage PD is a good clinical model to identify the symptoms that cause 
most disability, and even mortality, in patients who are severely disabled, highlighting the 
symptoms that should be targeted at an earlier stage of disease. Follow-up of patients in 
later stages will be valuable in estimation of the rate of motor and non-motor progression 
in advanced disease, which is known to differ from that in earlier stages.168 
Pathogenesis and neuropathology of late-stage levodopa-unresponsive symptoms are key 
areas for future PD research. Loss of dopaminergic neurons in the substantia nigra pars 
compacta is considered to be the key biological substrate for the classic motor features of 
PD.2 However, extranigral involvement has been extensively documented in PD, and has 
been implicated in the pathogenesis of levodopa-unresponsive motor symptoms and 
NMS.1,188,191-193 For example, loss of cholinergic neurons in the pedunculopontine nucleus 
and nucleus basalis of Meynert is thought to be crucial in the pathogenesis of the 
cognitive impairment, attention deficit, postural instability and falls, and visual 
hallucinations that are observed in late-stage PD.194,195 These emerging data have already 
led research to encompass neuronal systems beyond dopaminergic pathways. 
The Braak staging system1 suggests that the progression of α-synuclein accumulation 
follows a consistent pattern, beginning in the gut and gastric autonomic plexus of 
Meissner and olfactory nerve endings, ascending rostrally and ultimately reaching cortical 
areas. However, the presence of Lewy bodies containing α-synuclein in the cortex is 
neither necessary nor sufficient for impaired cognition,192,196 which questions the validity 
of the Braak staging system to explain all symptoms of PD.  
The importance of future research on disability milestones is twofold. First, it might 
promote the identification of new therapeutic targets for drug development. Second, 
these milestones may represent good candidates for clinical end points of future trials on 
disease progression.134 Disease milestones are, however, associated with considerable 
problems, which merit discussion. Therapeutic interventions aimed at disease milestones 
may lack efficacy on functional outcomes and disability, owing to the advanced stage of 
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disease at which these events occur. Moreover, if such milestones are used as end points 
for clinical trials of disease-modifying therapies, the experimental intervention would 
probably have to be initiated early in the disease course to allow a reasonable follow-up 
time in which to measure outcome. Such lengthy trials risk a high drop-out rate, face the 
threat of a change in clinical management of PD, and are expensive. 
CONCLUSIONS 
Mounting evidence suggests that at least a subset of patients with PD will progress to a 
late phase of disease in which disability is dominated by levodopa-resistant motor 
symptoms and NMS (Figure 1). This late-stage PD is characterized by a clinical phenotype 
that does not fit the common concept of advanced PD. Some patients who enter late-
stage PD will have had longer disease duration than other patients at the same disease 
stage, with earlier disease onset and motor complications that may, at some point, justify 
DBS because of severe disability. DBS will not, however, prevent the emergence of other 
sources of disability as disease progresses. Another group of patients will have had a 
shorter disease course, with older age at onset and few or no motor complications, and 
this group will eventually enter late-stage PD without prior DBS. 
Among the features of late-stage PD, falls, hallucinations, dementia and 
institutionalization represent milestones that start an exponential curve of disease pro-
gression, ending in death within approximately 5 years. Age at onset and disease duration 
only seem to determine how long the patient will remain milestone-free. Identification of 
the most disabling symptoms has direct implications for the focus of clinical care and 
research. 
A universal feature among patients with late-stage PD is complete loss of independence. 
We propose that this stage of PD should designate patients who are very dependent on 
caregivers for ADL, scoring less than 50% on the Schwab and England Scale during the ‘on’ 
period. This definition focuses on functional consequences of motor and non-motor 
parkinsonism, in contrast to late stages on the Hoehn and Yahr Scale, which place 
emphasis on postural instability and gait dysfunction. Discussion and validation of a 
suitable definition of late-stage disease should be the topic of future work, to address this 
increasingly common facet of the PD landscape. 
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Review criteria 
We searched PubMed for full-text papers published in English and French between 
January 1966 and April 2012 using the terms “Parkinson disease” and “advanced”, “late 
stage”, “staging”, “progression”, “nonmotor symptoms”, “nondopaminergic”, 
“environmental” and “pathology”. Reference lists of identified papers were manually 
searched for additional relevant studies. 
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ABSTRACT 
Late-stage Parkinson’s disease is characterised by patients dependent on caregivers for 
their activities of daily living, even under the best levodopa benefit. Non-motor signs that 
overcome the well-known motor signs of Parkinson’s disease dominate late-stage 
Parkinson’s disease and few systematic data exist for the treatment of these signs. The 
objective of this study was to review the treatment options for Parkinson’s disease 
dementia, psychosis, falls, bone fractures, joint and skeletal deformities, pain, orthostatic 
hypotension, gastrointestinal abnormalities and urological dysfunction in late-stage 
Parkinson’s disease. The study analysed the available controlled clinical trials for the 
above medical conditions. When absent, data from case series and the authors’ own 
experience was considered. Few controlled clinical trials specifically addressed late-stage 
Parkinson’s disease as a target population. There is a need for therapeutic data on the 
symptoms that most afflict late-stage Parkinson’s disease patients. 
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INTRODUCTION 
The cardinal signs of Parkinson’s disease are asymmetrical bradykinesia, rest tremor, 
rigidity and postural instability. Non-motor symptoms such as dementia, orthostatic 
hypotension and urinary dysfunction also occur frequently, mainly in advanced stages of 
the disease.33,34  
Disability in Parkinson’s disease is progressive due to the non-existence of an efficacious 
intervention to slow disease progression. Levodopa still remains the most effective drug 
for the symptomatic treatment of motor Parkinson’s disease. Yet, the emergence of 
motor complications and the lack of benefit in non-motor symptoms limits its usefulness 
and adds further disability.197,198 Although nearly 95% of patients experience motor 
complications in the later stages of Parkinson’s disease, the non-motor symptoms appear 
to be the ones most contributing to disability.56 
The first attempt to stage Parkinson’s disease according to levels of impairment or 
disability was done in the seminal paper by Hoehn and Yahr42 and it still holds today 
despite its shortcomings.82 The Hoehn and Yahr staging does not take into account motor 
complications, since it was defined before the levodopa era.42 Another classification 
currently used, but lacking formal definition, considers three stages in Parkinson’s 
disease: early, stable and advanced. Under this system, patients reach the advanced stage 
when they start fluctuating. Therefore, the advanced stage includes early fluctuators who 
are moderately disabled and far advanced patients who are much more disabled. 
The extreme of this spectrum, designated by late-stage Parkinson’s disease, should be 
distinguished from the early fluctuators, because those patients have very particular 
needs concerning healthcare. Late-stage Parkinson’s disease refers to patients who are 
dependent on caregivers for most of their activities of daily living, even under the best 
levodopa benefit (Hoehn and Yahr stage IV or V in an on period).42 At most, these patients 
will still be able to stand or walk unassisted for a short distance. In addition, non-motor 
symptoms are usually more frequent and severe than in less advanced stages.34,199 
This definition is based on a high level of disability, which is not contingent to the kind of 
impairments causing it. Yet, since it is anchored to the Hoehn and Yahr staging,42 it 
implies the presence of severe motor impairments. Nonetheless, it is known that non-
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motor impairments are probably the most important determinants of disability in later 
stages of Parkinson’s disease.56 
In future years, an increase in the prevalence of late-stage Parkinson’s disease is to be 
expected92,200 and this population will represent a heavy burden for their families and the 
healthcare system. Even so, little attention has been focused on the management of late-
stage Parkinson’s disease and these patients are not usually captured in clinical trials.  
Considering non-motor symptoms as the main cause of disability in far advanced stages56 
and that motor complications have been recently and deeply reviewed elsewhere,201-205 
this study intends to review the available treatment options for non-motor symptoms in 
late-stage Parkinson’s disease. The study chose those most potentially contributing to 
disability in this population: dementia, psychosis, falls, bone fractures, joint and skeletal 
deformities, pain, orthostatic hypotension, gastrointestinal abnormalities and urological 
dysfunction. 
This review has included only data based on controlled clinical trials. An exception is 
made in the Expert Opinion section, where data from case series and personal experience 
were incorporated.  
MATERIAL & METHODS 
Objective: to review the evidence on the pharmacological and non-pharmacological 
interventions to treat non-motor symptoms in late-stage Parkinson’s disease. 
We selected to review those non-motor symptoms responsible for most disability of PD 
patients in later stages of the disease: dementia, psychosis, falls, bone fractures, joint and 
skeletal deformities, pain, orthostatic hypotension, gastrointestinal abnormalities and 
urological dysfunction. This choice was based on the results from the Sydney cohort56-57 
and our own findings reported in Chapters 1 and 2. 
We searched PubMed and Cochrane Library for full-text papers of controlled clinical trials 
(CCT) or systematic reviews published in English, French, Spanish or Portuguese between 
January 1966 and December 2007, using the terms “Parkinson’s disease” and “advanced”, 
“late stage”, “non motor symptoms”, “dementia”, “psychosis”, ”hallucinations”, “falls”, 
“bone fractures”, “striatal hand”, “striatal foot”, “camptocormia”, “Pisa syndrome”, 
“frozen shoulder”, “scoliosis”, “pain”, “orthostatic hypotension”, “sialorrhea”, 
“dysphagia”, “delayed gastric emptying”, “constipation”, “nocturia”, “urinary urgency”, 
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“urinary frequency” and “incontinence”. Reference lists of identified papers were 
manually searched for additional relevant studies. 
In the Expert Opinion section, data from case series and personal experience were 
additionally incorporated.  
MANAGEMENT OF LATE-STAGE PARKINSON´S DISEASE 
1. Dementia 
Patients with clinical suspicion of Parkinson’s disease dementia should have a blood and 
urine work-up, a neuroimaging study (brain CT or MRI) and their medications reviewed in 
order to exclude treatable causes of cognitive decline. 
If a work-up is negative, specific pharmacotherapy could then be tried. The best-studied 
drugs in Parkinson’s disease dementia are the acetylcholinesterase inhibitors rivastigmine 
and donepezil. There are no controlled clinical trials on galantamine or memantine for 
Parkinson’s disease dementia.206 
1.1 Rivastigmine 
A 24-week, randomised, double-blind, parallel-group, placebo-controlled trial179 was 
conducted in 541 patients with mild-to-moderately severe dementia with onset at least 2 
years after diagnosis of Parkinson’s disease. A total of 131 patients discontinued the study 
prematurely, mainly due to adverse events (17.1% of patients on rivastigmine and 7.8% of 
patients on placebo). Improvements favoured rivastigmine for the Alzheimer’s Disease 
Assessment Scale (ADAS – cog) (p < 0.001) and the Alzheimer’s Disease Cooperative 
Study-Clinician’s Global Impression of Change Scale (ADCS – CGIC) (p = 0.007). The most 
frequent adverse events were nausea (29% on rivastigmine and 11.2% on placebo) (p < 
0.001) and vomiting (16.6% on rivastigmine and 1.7% on placebo) (p < 0.001), while 
serious adverse events were similar between the groups. Rivastigmine was associated 
with parkinsonism exacerbation (27.3 versus 15.6%) (p = 0.002), mainly tremor (10.2 
versus 3.9%) (p = 0.01), but this was not clinically relevant. An active extension study,207 
with assessments at 48 weeks, replicated the above results. 
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1.2 Donepezil 
A randomised, double-blind, cross-over, placebo-controlled trial included 22 patients who 
had mild-to-moderate dementia developing ≥ 12 months after parkinsonism.208 Donepezil 
had a statistically non-significant improvement for the ADAS-cog (p = 0.18). The scores in 
the Mini Mental State Examination (MMSE) (p < 0.004) and the Clinical Global Impression 
of Change (p < 0.005) significantly favoured donepezil compared to placebo, but the same 
was not true for the Mattis Dementia Rating Scale or the Brief Psychiatric Rating Scale. 
Adverse events occurred equally in both groups, the most frequent being worsening of 
psychosis and agitation.208 
A randomised, double-blind, cross-over, placebo-controlled trial209 enrolled 14 
Parkinson’s disease patients with clinical evidence of impairment in memory (an MMSE 
score of 16 – 26) and at least one other cognitive domain, which had an onset ≥ 12 
months after parkinsonism. Donepezil resulted in a significant improvement in the scores 
for the MMSE (p = 0.01) and the Clinician’s Interview Based Impression of Change plus 
Caregiver Input (CIBIC+) (p = 0.03). Three patients on donepezil withdrew due to adverse 
events. Parkinsonism did not aggravate with donepezil. 
Another randomised, double-blind, parallel, placebo-controlled, 18-week trial210 enrolled 
a mixed population of 16 Parkinson’s disease patients with either a diagnosis of dementia 
or cognitive impairment associated with Parkinson’s disease, but the authors did not state 
the interval between parkinsonism and cognitive impairment onset. Four patients on 
donepezil withdrew due to adverse events (parkinsonism aggravation = 1). Significant 
differences favouring donepezil were found only in the memory subscale of the Dementia 
Rating Scale (p < 0.05). 
2. Psychosis 
In patients presenting with psychosis, a good history is key in identifying the causes. 
Attention should first be drawn to any recent change in medication, to metabolic 
aetiologies and to infections. Brain CT or MRI may prove necessary to exclude a structural 
lesion. Those patients with drug-induced psychosis should be started on antipsychotics, 
when no further reduction of antiparkinsonian medication is possible due to motor 
symptoms. The choice should be among atypical neuroleptics, as classical antipsychotics 
severely worsen parkinsonism. 
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There are six marketed atypical neuroleptics: clozapine, quetiapine, risperidone, 
olanzapine, ziprasidone and aripiprazole. Controlled clinical trials are only available for 
clozapine, quetiapine and olanzapine.206 A randomised clinical trial comparing clozapine 
with olanzapine was prematurely stopped because of a severe deterioration in 
parkinsonism with olanzapine.211 Case series reporting on risperidone,212-213 
ziprasidone,214-216 and aripiprazole217-219 have described a deterioration in motor function 
with these drugs. 
2.1 Clozapine 
The Parkinson Study Group220 randomised 60 patients with Parkinson’s disease and drug-
induced psychosis in a parallel-group, double-blind, 4-week trial to either placebo or low-
dose clozapine. The patients had a mean age of 71 years. The psychosis outcome 
measures were highly statistically significant in favour of clozapine compared to placebo. 
Regarding safety, six drop-outs occurred: for clozapine these were due to reversible 
leucopaenia (one patient), myocardial infarction (one patient) and sedation (one patient), 
while for placebo these were due to an increase in psychosis (two patients) and 
pneumonia (one patient). The mean neutrophile white cell blood counts and orthostatic 
blood pressures were similar in both treatment arms, but there was a significantly small 
increase in the heart rate with clozapine. Important safety issues further arose during and 
after the extension phase on clozapine (n = 53) with one drop-out due to reversible 
leucopaenia and nine deaths due to stroke (one patient), cardiac arrest (one patient), 
pneumonia (two patients), bronchitis (two patients) and unknown causes (three 
patients). Clozapine was not associated with parkinsonism aggravation. 
A randomised, parallel, placebo-controlled trial221 consisting of a double-blind phase (4 
weeks) followed by an open-label period (12 weeks) enrolled 60 patients with an MMSE 
score ≥ 20 who were experiencing drug-induced psychosis. Primary outcome measures 
significantly favoured clozapine compared to placebo. Overall, adverse events were more 
frequent with placebo, though somnolence and reversible neutropenia (two patients) 
were more frequent with clozapine. Two patients died (one sudden death and one due to 
aspiration pneumonia). Once again, the Unified Parkinson’s Disease Rating Scale (UPDRS) 
motor scores did not differ between treatments. 
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Other than leucopaenia, the use of clozapine has been associated with severe myocarditis 
and cardiomyopathy,222-224 acute interstitial nephritis225-226 and venous 
thromboembolism.227 
2.2 Quetiapine 
Thirty-one Parkinson’s disease patients with drug-induced psychosis and a MMSE score > 
21 were randomised to placebo or quetiapine in a double-blind, parallel-group, placebo-
controlled, 12-week study.228 The results did not show significant differences in the 
efficacy measures between quetiapine and placebo. Another trial that included 58 
patients with drug-induced psychosis (29 patients demented) found similar results.229 
 
3. Falls 
Falls in late-stage Parkinson’s disease may arise due to gait impairment, namely freezing 
of gait, postural instability, involuntary movements such as dyskinesias or foot dystonia, 
orthostatic hypotension or psychosis and confusion.230 An approach to falls should begin 
by eliminating precipitant factors such as drug-induced psychosis, taking general 
measures such as removing domestic hazards or adjusting antiparkinsonian therapy.230 
This study found controlled clinical trials using falls as an outcome for the interventions 
outlined below. 
3.1 Physiotherapy 
Two systematic reviews assessed the efficacy of physiotherapy compared to placebo or 
no intervention in Parkinson’s disease.231,232 The authors found insufficient evidence to 
support or refute the use of physiotherapy in Parkinson’s disease, while another 
systematic review,233 using a broader definition for ‘exercise therapy’, concluded that 
these interventions are probably effective in improving functional outcomes, though this 
improvement is small and transitory. 
Nieuwboer et al.234 included 153 Parkinson’s disease patients in a single-blind, 
randomised, cross-over trial in order to evaluate the use of a home physiotherapy 
programme, compared to no intervention on gait and gait-related activity (the RESCUE 
trial). Patients had mild-to-severe postural instability, no cognitive impairment and no 
unpredictable and long-lasting off periods. The primary outcome was the posture and gait 
score, a composite score of the gait and balance UPDRS items. Falls were a safety 
     Treatment of non-motor symptoms in Late-stage PD 
 
 
129 
 
measure. The results did not show a significant change in the number of falls with the use 
of physiotherapy, compared to no intervention (p = 0.4). 
Protas et al.235 conducted an 8-week, randomised, parallel, assessment-blinded, no 
intervention-controlled trial in order to assess the efficacy of gait and step perturbation 
training in reducing the number of falls and improving gait in 18 men with Parkinson’s 
disease. The trial included patients who had a postural instability gait-predominant 
Parkinson’s disease and experienced freezing episodes or had a history of falls and were 
cognitively well. The results showed a non-significant trend to fewer falls with the active 
intervention compared to the control group. 
3.2 Occupational therapy 
Two systematic reviews231,236 found insufficient evidence to support or refute the use of 
occupational therapy in Parkinson’s disease compared to placebo or no intervention. 
Instead, another systematic review233 found that ‘exercise therapy’, including 
occupational therapy, probably had a small and transitory benefit in improving functional 
outcomes in Parkinson’s disease. 
3.3 Risedronate 
Please refer to the section below on Bone Fractures. 
3.4 1α-Hydroxyvitamin D3 
Please refer to the section below on Bone Fractures. 
4. Bone fractures 
Bone fractures associated with osteoporosis and resulting from falls contribute to 
immobilisation, which in turn further aggravates osteoporosis and the risk of future 
falls.230 Prevention of bone fractures is a result of avoiding falls (see above) and reducing 
osteoporosis. 
4.1 Alendronate 
Sato et al.237 conducted a 2-year, randomised, double-blind, parallel, placebo-controlled 
trial in order to evaluate the efficacy and safety of the combined therapy alendronate 
plus vitamin D2 (ergocalciferol) in reducing the risk of hip fractures and controlling 
osteoporosis. The trial included 288 elderly women with Parkinson’s disease and excluded 
patients in Hoehn and Yahr stage 5. The patients were randomised to alendronate (5 
mg/day) plus ergocalciferol (1000 IU/day) or placebo plus ergocalciferol (1000 IU/day). 
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Withdrawals were similar between the groups. The incidence of hip fractures was four 
patients in the alendronate arm versus 14 patients in the placebo arm. The patients’ bone 
mass density increased 3.1% in the alendronate group and decreased 2.8% in the placebo 
group (p < 0.0001). The adverse events with alendronate were leucopenia (one patient), 
oesophagitis (two patients) and diarrhoea (three patients), while three patients on 
placebo suffered from abdominal pain. No serious adverse events occurred. 
4.2 Risedronate 
Sato et al.238 evaluated the efficacy and safety of risedronate in the risk of hip fractures 
and osteoporosis in 242 elderly men with Parkinson’s disease in a 2-year, randomised, 
double-blind, parallel, placebo-controlled trial. Patients in Hoehn and Yahr stage 5 [6] 
were excluded. Patients were randomised to risedronate (2.5 mg/day) plus ergocalciferol 
(1000 IU/day) or placebo plus ergocalciferol (1000 IU/day). Withdrawals were similar 
between the groups. The incidence of hip fractures was three patients with risedronate 
versus nine patients with placebo. There was no significant difference in the number of 
falls between treatments. The patients’ bone mass density increased 2.2% in the 
risedronate group and decreased 2.9% in the placebo group (p < 0.0001). The adverse 
events with risedronate were abdominal pain (four patients) and oesophagitis (three 
patients), while three patients on placebo suffered from abdominal pain or discomfort. 
No serious adverse events occurred. 
4.3 1 α-Hydroxyvitamin D3 
Sato et al.239 tested the efficacy and safety of 1α-hydroxyvitamin D3 (1α(OH)D3, an active 
form of vitamin D) in increasing the bone mass density and in reducing the incidence of 
non-vertebral fractures in a double-blind, randomised, placebo-controlled trial. Patients 
in Hoehn and Yahr stage 5 were excluded. Eighty-six Parkinson’s disease patients were 
randomised to either 1α(OH)D3 (1 μg/day) or placebo. After 18 months the incidence of 
fractures was significantly less in the active arm compared to placebo (one versus eight, 
respectively) (p = 0.003). The patients’ bone mass density decreased 1.2% in the 
treatment group versus 6.7% in the placebo group (p < 0.0001). The number of falls was 
similar between both treatments. The authors did not report the occurrence of adverse 
events. 
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5. Joint and skeletal deformities 
Several joint and skeletal deformities affect Parkinson’s disease patients in later stages of 
the disease, namely striatal hand and foot, camptocormia (bent spine), Pisa syndrome (or 
pleurothotonus, a persistent flexion of the body and head to one side and axial rotation 
of the trunk), scoliosis and anterocollis.240 These deformities have a differential diagnosis 
from lesions from rheumatoid arthritis or orthopaedic disorders. The available treatment 
options include antiparkinsonian drugs, botulinum toxin, baclofen and benzodiazepines, 
orthopaedic surgery and functional neurosurgery, although none has been tested under a 
controlled clinical trial protocol. Shoulder lesions, such as frozen shoulder and rotator cuff 
syndrome, are also experienced by late-stage Parkinson’s disease patients and will mainly 
cause pain and limitation of joint movement (refer to section on Pain).241,242 
6. Pain 
The overall approach to pain in Parkinson’s disease begins by individualising the type of 
pain the patient is reporting. Pain in Parkinson’s disease can be categorised as either 
dystonic-associated or non-dystonic-associated pain, such as central, neuropathic or 
radicular, musculoskeletal and akathisia discomfort.243 The choice of pharmacological and 
non-pharmacological interventions will depend on the above categories of pain, taking 
into consideration the possible coexistence of different pain syndromes in the same 
patient. As most pain is usually associated with a worsening of motor disability, 
adjustment of antiparkinsonian medication is generally the first step in controlling 
Parkinson’s disease-associated pain.243,244 No controlled clinical trials on the treatment of 
pain in Parkinson’s disease were found.  
7. Orthostatic hypotension 
Orthostatic hypotension can result from Parkinson’s disease itself and/or be secondary to 
dopaminergic drugs. The concomitant use of antihypertensives adds to this side effect of 
dopaminergic drugs. In some patients the symptoms of orthostatic hypotension are 
features of non-motor fluctuations and, thus, adjustment of antiparkinsonian medication 
will benefit these patients. The prescription of non-pharmacological treatments, such as 
water ingestion, raising the head of the bed and increasing salt ingestion, may be of 
benefit, even though evidence is lacking for the majority of these interventions.245 The 
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drugs most commonly used for orthostatic hypotension are midodrine, a selective 
peripherally acting α-adrenergic agonist and fludocortisone, a salt-retaining 
mineralocorticoid. 
7.1 Midodrine 
A systematic review231 identified two level-1 placebo-controlled trials in a mixed 
population of patients, including Parkinson’s disease. In both studies, midodrine was 
significantly superior to placebo in increasing blood pressure, but it was associated with 
supine systolic hypertension and cardiovascular adverse reactions. The heterogeneity of 
the samples in these studies did not allow any conclusions to be drawn on the efficacy of 
midodrine in Parkinson’s disease. 
7.2 Fludocortisone, etilefrine, L-threo-3,4-dihydroxyphenylserine and yohimbine 
The same systematic review231 as above identified one trial for each of the interventions 
fludocortisone, etilefrine and L-threo-3,4-dihydroxyphenylserine in small Parkinson’s 
disease samples. According to the authors, the evidence was insufficient to support their 
use in Parkinson’s disease. The results of one trial in 17 Parkinson’s disease patients 
showed that yohimbine is non-efficacious for treating orthostatic hypotension in 
Parkinson’s disease.231  
8. Gastrointestinal dysfunction 
Several gastrointestinal abnormalities are experienced by late-stage Parkinson’s disease 
patients, namely dysphagia, drooling, delayed gastric emptying and constipation, while 
others like small bowel mal-absorption remain to be replicated.246,247 The management of 
these gastrointestinal complications is aimed at the symptoms they cause, such as 
dysphagia, early satiety and abdominal discomfort and the interference they cause in 
levodopa pharmacokinetics. Therapeutic strategies to overcome disturbed levodopa 
pharmacokinetics are not the aim of this review. 
8.1 Dysphagia 
No controlled clinical trial has assessed the efficacy of pharmacological or non-
pharmacological interventions for dysphagia in Parkinson’s disease.248,249 The insertion of 
a nasogastric or percutaneous gastrostomy tube is a common practice in late-stage 
Parkinson’s disease, although no data are available regarding their effect on survival or 
quality of life. 
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8.2 Sialorrhea 
8.2.1 Botulinum toxin 
Lagalla et al.250 investigated the safety and efficacy of 50 U of botulinum toxin type A 
(Botox®) in the treatment of sialorrhea in 32 Parkinson’s disease patients in a double-
blind, randomised, parallel, placebo-controlled trial. Botulinum toxin was injected into 
each parotid gland without using ultrasound guidance. Patients with dysphagia requiring 
soft food were excluded. Botulinum toxin was associated with a statistically significant 
reduction in drooling frequency, familial and social disability and saliva production 
compared to placebo. One patient treated with botulinum toxin complained of transient 
dysphagia. These results have been replicated in other trials.251-254 A small study 
comparing ultrasound-guided versus ‘blind’ injection of botulinum toxin type A in parotid 
glands seemed to favour ultrasound-guided injections.255 
The efficacy and safety of botulinum toxin type B was evaluated in 16 Parkinson’s disease 
patients in a double-blind, randomised, parallel, placebo-controlled trial.256 Botulinum 
toxin or placebo was injected into each parotid gland (1000 U) and each submandibular 
gland (250 U) using anatomic landmarks. Patients injected with botulinum toxin reported 
a statistically significant improvement in drooling compared to placebo: the adverse 
events with botulinum toxin were mild and included a dry mouth (three patients), 
worsened gait (two patients), diarrhoea (one patient) and neck pain (one patient). 
8.2.2 Anticholinergics 
A randomised, double-blind, placebo-controlled, cross-over study in 17 Parkinson’s 
disease patients investigated the benefit of sublingual ipratropium bromide spray.257 
Ipratropium bromide failed to show significant efficacy in the primary outcome, the 
weight of saliva production, compared to placebo, although it showed a mild effect in 
subjective measures of sialorrhea. There were no significant adverse events. 
8.3 Delayed gastric emptying and constipation 
8.3.1 Domperidone 
One level-2 trial identified by a systematic review231 found domperidone to be efficacious 
in reducing the duration of gastrointestinal emptying, in Parkinson’s disease patients 
treated with levodopa. 
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8.3.2 Tegaserod 
Tegaserod is an FDA-approved partial 5-HT4 agonist for the short-term treatment of 
women with constipation from irritable bowel syndrome. A pilot, double-blind, 
randomised, parallel, placebo-controlled trial evaluated the efficacy and safety of 
tegaserod in 15 Parkinson’s disease patients with constipation.258 The results showed a 
trend for decreased constipation in the active arm compared to placebo and a lack of 
adverse events with tegaserod. 
8.3.3 Macrogol 
Zangaglia et al.259 tested the use of an isosmotic macrogol electrolyte solution for 
constipation in 57 Parkinson’s disease patients, in an 8-week, randomised, double-blind, 
parallel, placebo-controlled study. The primary efficacy measure was the responder rate 
regarding constipation symptoms. Dietary habits and water ingestion were kept 
unchanged during the trial, in contrast to the intake of fibre. Withdrawals (n = 14) were 
higher with macrogol compared to placebo (31 versus 18%) and were not included in the 
final analysis. This analysis showed a statistically significant difference in the responder 
rates favouring macrogol (p < 0.001). 
8.3.4 Cisapride 
The use of cisapride has been associated with cardiac arrhythmias and sudden deaths and 
possibly aggravation of parkinsonism, which precludes its use in Parkinson’s disease due 
to an unacceptable risk.231 The US FDA has discontinued its use due to the risk of fatal 
arrhythmia.  
9. Urological dysfunction 
Urological problems in Parkinson’s disease are usually associated with bladder 
dysfunction due to detrusor muscle hyperactivity, resulting in nocturia, urinary urgency 
and frequency and urge incontinence.260 The overall approach should start by ruling out 
urinary tract infection and, in men, outflow obstruction by benign prostatic 
hyperplasia.260 Anticholinergics are the most commonly used drugs for detrusor muscle 
hyperactivity, but no data based on controlled clinical trials are available regarding their 
use in Parkinson’s disease.231,260  
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EXPERT OPINION 
Late-stage Parkinson’s disease stands at a phase of complex therapeutic management. 
Different phenomena can co-occur, namely severe motor impairment, predictable motor 
complications responsive to levodopa, unpredictable motor complications unresponsive 
to most available interventions, non-motor symptoms unresponsive to levodopa and with 
few efficacious alternative interventions and symptoms that endanger life such as 
dysphagia or, indirectly, bone fractures. Furthermore, drugs that benefit one condition 
(e.g., anticholinergics for urinary dysfunction) aggravate others in the same patient 
(dementia or psychosis). The first step in managing late-stage Parkinson’s disease should 
be defining the therapeutic goal and respective outcome in an individual patient, knowing 
a priori this is a difficult and time- and cost-consuming task. 
When facing a clinical diagnosis of Parkinson’s disease dementia treatable causes should 
be excluded first (Table 1). If a work-up is negative, specific pharmacotherapy can then be 
tried using the acetylcholinesterase inhibitors rivastigmine or donepezil. Up to now 
rivastigmine has been the best-studied drug in Parkinson’s disease dementia. Its mean 
effect is modest and long-term data extend to just 48 weeks. More evidence is necessary 
to support or refute long-term use beyond that time point. One should monitor the 
progression of dementia to establish when no further gains from acetylcholinesterase 
inhibitors are likely to occur, although stopping medication may be hampered by 
caregivers’ expectations. 
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Similarly, the first step in treating psychosis is to search for treatable causes (Table 2).261 
Drug-induced psychosis can occur even after small changes in medication, is typically 
dose dependent and, thus, usually ameliorates after dose adjustment or medication 
withdrawal. The last added drug should be the first to be reduced or withdrawn. The 
usual culprits are anticholinergics, selegiline or amantadine. Next, dopamine agonists 
should be reduced or eliminated: if psychosis persists, catechol-O-methyl transferase 
(COMT) inhibitors and controlled-released levodopa are then down-titrated or excluded. 
If still necessary, levodopa will be reduced, with the bedtime dose being first. Of note is 
that tricyclic antidepressants have an anticholinergic activity. 
When specific treatment is warranted, low-dose clozapine is the best choice, though 
blood monitoring and potential dangerous side effects hamper its use. The usual doses of 
clozapine are < 25 mg/day, with many patients responding to 6.25 mg/day. We are aware 
that many experts do not consider clozapine as first-line treatment, based on the above 
safety issues and practicability and alternatively favour quetiapine. Present available data 
do question quetiapine efficacy and raise concerns about its safety. Therefore it cannot 
be recommended as a first-line drug until the matter is clarified, which might mean the 
definition of a proper dose. There is an urgent need for an efficacious antipsychotic 
without the risk of serious adverse events or aggravation of parkinsonism. 
 
 
 
 
 
Table 1. Management of Parkinson’s disease dementia 
Review medication (special attention to anticholinergics) 
Blood and urine work-up (including thyroid function tests, vitamin B12 and folic acid level, and exclusion 
of infection) 
Neuroimaging (CT or MRI) to exclude structural lesions such as a subdural hematoma  
If work-up negative use acetylcholinesterase inhibitors rivastigmine or donepezil 
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COMT: Catechol-O-methyl transferase. 
 
Falls in late-stage Parkinson’s disease may derive from postural instability, gait problems, 
namely freezing, involuntary movements, syncope or postural hypotension and delirium 
or psychotic symptoms.262 One should first identify which factor(s) most contribute to 
falls in a particular patient and then target the intervention accordingly. 
If iatrogenic in origin, withdrawal of cause should be attempted. Reduce on period 
medication when dyskinesias and/or excessive mobility are the main cause of falls.262 
Reduce dopamine agonists when facing orthostatic hypotension or syncope and 
introduce specific non-pharmacological and pharmacological measures for orthostatic 
hypotension if necessary.262 Reduce or stop drugs inducing delirium/psychosis and 
evaluate hypothetic dementia.262 If falls are mainly caused by postural instability or 
freezing, increasing dopaminergic drugs should be tried, chiefly if the symptoms are 
mostly present during off periods.262 Balance dysfunction may partially alleviate with 
increasing dosage of levodopa and off period freezing usually responds to levodopa.262 Of 
note is that dopamine agonists were associated with an increased frequency of 
Table 2. Management of psychosis  
Look for recent institutionalization or home change 
Blood and urine work-up to exclude infection, dehydration or metabolic imbalance 
Look for falls. If appropriate, ask for neuroimaging (CT or MRI) to exclude structural lesions such as a 
subdural hematoma 
Review recent change or adding in medication. Start by adjusting dose of most recent changed / added 
drug   
If no recent change,  adjust first anticholinergics, selegiline or amantadine 
Reduce or eliminate dopamine agonists  
If psychosis persists,  reduce or eliminate COMT inhibitors and controlled-released levodopa formulations 
If necessary, reduce levodopa (bedtime dose first) 
If insufficient, begin clozapine 6.25 mg bedtime and titrate accordingly. Monitor blood and cardiac side 
effects 
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freezing.262 Further discussion on the treatment of freezing or postural instability is 
beyond the topic of this review. 
Evidence suggests that, at best, physical rehabilitation, as a whole, is mildly effective with 
a transient benefit in improving freezing, gait mobility and falls. Training targeted at falls 
may be worth a try in non-demented patients. We may speculate whether passive 
movement of joints will by itself have some impact on survival, for instance by reducing 
pulmonary embolism: moreover, passive movement of joints is easily performed by 
caregivers at no cost. Other non-pharmacological interventions might reduce falls or the 
morbidity from falls, namely removing domestic hazards, using proper footwear and 
walking aids and reducing alcohol intake: in addition, the treatment of osteoporosis will 
reduce the incidence of bone fractures from falls (see below).230 
Osteoporosis in late-stage Parkinson’s disease can be effectively treated using 
alendronate or risedronate associated with vitamin D2 or 1α-hydroxyvitamin D3, but 
bedridden patients will no longer benefit from these drugs. However, since these drugs 
take more than 1 year to have an effect and the gastric upset decreases compliance, their 
effectiveness might be lower than the reported efficacy. 
Abnormal postures of the limbs, neck and trunk frequently complicate late-stage 
Parkinson’s disease. A correct differential diagnosis with other clinical entities should be 
the first approach, such as rheumatoid arthritis, Dupuytren’s contracture, de Quervain’s 
tenosynovitis of fingers, entrapment neuropathies, cervical myelopathies or babinski 
sign.240,263 
Joint deformities, such as striatal hand and foot, are unilateral as a rule and lack the 
typical local inflammatory signs of rheumatoid arthritis.263 Some clinical features of 
striatal hand and foot overlap with other forms of dystonia and, thus, they must be 
differentiated from dystonia as a complication of pharmacotherapy and from those 
features associated with functional neurosurgery for Parkinson’s disease.263 In addition to 
typical striatal deformity, patients may develop severe flexion contracture of the fingers, 
leading to abrasion and secondary infection.263 The rapid development of such 
contractures should bring attention to drug-induced reactive fibrosis in patients taking 
ergot dopamine agonists.263 Striatal hand and foot may respond to levodopa and 
anticholinergics and some reports have described benefit with baclofen and 
benzodiazepines.263 The preferred treatment is the injection of botulinum toxin in the 
     Treatment of non-motor symptoms in Late-stage PD 
 
 
139 
 
affected muscles, namely in the lumbricals and short adductors of the thumb, though the 
benefit will depend on the severity of fixed contracture.263 In more severe cases, 
orthopaedic surgery can be attempted and some authors have also reported benefit with 
thalamotomy.264 
A trial with levodopa or anticholinergics should be tried in patients with camptocormia or 
Pisa syndrome, who usually have a combination of rigidity and dystonia.240 Patients with 
camptocormia and associated rectus abdominus contraction can transiently benefit from 
local injection of botulinum toxin.265 In some, these postural deformities are secondary to 
cholinesterase inhibitors or antipsychotics, in which instances withdrawal of the offending 
drug is mandatory.266 
Pain in Parkinson’s disease was found to be strongly associated with motor fluctuations 
(adjusted odds ratio 8.6 and 95% CI = 2.1 – 35.9) (p = 0.003) and dyskinesias (adjusted 
odds ratio 5.1 and 95% CI = 1.6 – 15.7) (p = 0.005).243 This association was true for 
dystonic- and non-dystonic-type pain, in particular musculoskeletal pain. There was also a 
significant correlation between the severity of pain and severity of motor complications. 
This same study found a lack of association between pain and medical diseases 
potentially associated with pain in the general population. Dystonic and non-dystonic 
pain were mostly reported during maximal disability (off period) and peak dose dystonia 
and during begin-dose or end-dose dystonia in a lesser frequency of cases. In most cases, 
adjustments of levodopa resulted in decreased dystonic and non-dystonic pain. Based on 
this and other reports,267-268 it is suggested adjusting dopaminergic medication as the first 
step in treating Parkinson’s disease-associated pain. Patients with severe pain during an 
off period may also benefit from intermittent apomorphine or botulinum toxin 
injections.244 
In those patients not responding to dopaminergic drugs adjustment, an evaluation should 
be performed to rule out musculoskeletal and neuropathic/radicular pain, namely rotator 
cuff syndrome, frozen shoulder, cervical and lombar spondylosis and, less frequently, a 
cardio-respiratory disorder.241 Therapy should then be directed accordingly.244 When 
facing a suspicion of central or primary pain, the use of duloxetine is an option.241 Where 
duloxetine is not a practical choice, a trial with tricyclics antidepressants or anti-epileptics 
could be tried. 
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Late-stage Parkinson’s disease patients may also experience frozen shoulder, 
characterised by the insidious onset of pain, stiffness and loss of active and passive 
forward elevation and external rotation of shoulder.242 The natural history is for recovery 
in ∼ 30 months, but resolution may not be complete.242 During the first, painful phase of 
disease, joint movements causing pain should be discouraged and NSAIDS can be given to 
alleviate pain:242 patients benefit from intra-articular steroid injection, which is most 
effective when combined with physiotherapy and given early in the course of disease.269 
Physiotherapy alone is of limited value.269,270 During the second, adhesive phase, 
treatment must focus on physiotherapy, and steroid injections are no longer indicated.242 
The management of orthostatic hypotension should start by checking whether patients 
are taking antihypertensives or α blockers to treat prostate hyperplasia. If so, a judicious 
decrease in its dose should be attempted. Whenever possible, reducing the dose of 
agonists or, alternatively, of levodopa will be of help. An exception is made when 
hypotension symptoms are part of non-motor fluctuations, which implies adjustment of 
antiparkinsonian medication. 
There is a lack of evidence to support the prescription of most non-pharmacological 
interventions for orthostatic hypotension in Parkinson’s disease and, additionally, some 
of them are associated with low compliance (Table 3).245,271-273 With regard to water 
ingestion, it is known that the volume of ingested water influences the pressor response 
and that the pressor effect lasts for ∼ 1h.274,275 
When non-pharmacological interventions prove insufficient or non-compliant, 
pharmacotherapy should be started (Table 4).245,271-273 Although direct evidence is 
lacking, a first attempt with domperidone should be tried because of its additional effects 
on nausea, vomiting, gastroparesis and constipation. Midodrine should then be started 
and fludocortisone added later if necessary.271,272 Midodrine is started at a dose of 2.5 
mg/day and increased to a maximum of 10 mg, while fludrocortisone can be initiated at a 
dose of 0.1 mg/day and gradually increased.199 Their use is best restricted to a dose in the 
early morning and early afternoon, when the symptoms are worst, taken 30 – 45 min 
before activity.199,245,271-272 An important side effect is supine hypertension, especially at 
night and so it is critical to have supine blood pressure monitored.199,245,271,272,276 Night-
time supine hypertension worsens orthostatic hypotension because it induces pressure 
natriuresis, causing volume depletion.276 In addition, it increases the risk of cardiovascular 
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events and end-organ damage.276,277 When severe, night-time supine hypertension 
requires treatment (Table 4).271,272,276 
A recent trial, in a heterogeneous population of 58 patients with neurogenic orthostatic 
hypotension (including multiple system atrophy and pure autonomic failure patients), 
found pyridostigmine, alone or associated with midodrine, reduced orthostatic symptoms 
without causing supine hypertension.278 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: OH, orthostatic hypotension 
 
 
 
  
Table 3. Non-pharmacologic interventions for orthostatic hypotension  in  late-stage 
Parkinson`s disease 
Increase water ingestion, especially in the morning. This may worsen nocturia or urinary 
incontinence  
Liberal salt intake with foods 
Avoidance of sudden head up postural change and standing still for a prolonged period of time 
Avoidance of prolonged recumbence during daytime, is better to rest in a chair 
Use of portable chairs during ambulation 
Use of elastic abdominal binders and compression stockings (recommended to be thigh or 
waist high); stockings are associated with poor compliance 
Soft exercise of leg and abdominal muscles, leg crossing, and avoidance of straining during 
micturition and defecation 
Small frequent meals with reduced refined carbohydrate content, to prevent postprandial 
hypotension;  restriction of alcohol 
Avoidance of hot temperatures 
During the night, lift the head of bed to diminish nocturnal sodium loss and improve OH in the 
morning. 
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Dysphagia is a dramatic concern, putting life in danger and so requiring a pragmatic 
intervention, even in the face of few available data. Non-pharmacological swallowing 
therapy by trained personnel could be tried. Some patients may improve with 
dopaminergic drugs, while anticholinergics should be withdrawn, as they were reported 
to worsen disphagia.279 Insertion of a percutaneous gastrostomy tube to prevent choking 
and aspiration pneumonia and to tranquillise patients and caregivers is advisable when 
dysphagia becomes severe. One should inform patients and caregivers that oral feeding is 
still possible after gastrostomy (for example, to eat tasty food), as this seems to be a usual 
concern. Patients may suffer from other oesophageal abnormalities, such as non-
peristaltic swallowing, segmental spasms, oesophageal dilatation and gastro-oesophageal 
reflux.280 In these instances, dopaminergic drugs seem to offer no benefit and 
anticholinergics may again aggravate these symptoms, as oesophageal motility depends 
mostly on cholinergic mechanisms.281 Other oesophageal symptoms, such as belching, 
can be related to motor fluctuations and may disappear during on periods.282 
Drooling saliva, as the result of inefficient and infrequent swallowing, is more prevalent in 
later stages of Parkinson’s disease and during off periods.246 In those patients whose 
dysphagia improves during on phases, dopaminergic drugs are a good first attempt to 
control drooling.246 Otherwise, patients should be treated with botulinum toxin injections 
of either A or B serotype. If this is not feasible, sublingual administration of atropine 
ophthalmic solution could be tried before meals. This option prevents the systemic side 
effects and the aggravation of swallowing by oral anticholinergics. Tricyclic 
Table 4. Pharmacologic interventions for  orthostatic hypotension  in  late-stage Parkinson`s 
disease 
Start  pharmacotherapy when non-pharmacologic interventions are insufficient or non-compliant 
Try domperidone first 
Begin midodrine 
Add fludocortisone latter, if necessary. Monitor metabolic imbalance 
Instruct patients taking pressor drugs not to lye down after each dose 
Avoid pressor drugs intake in the evening and water boluses at bedtime 
Monitor supine blood pressure, especially at night 
If nighttime supine hypertension:  transdermal nitroglycerin, nifedipine, hydralazine, or 
clonidine. Clonidine also reduces nocturnal natriuresis 
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antidepressants, such as amitriptyline, in low doses at bedtime are another possible 
approach to sialorrhea. 
Gastroparesis is an issue of major concern. The factors probably associated with it are 
food bulk, its composition in lipids and carbohydrates, constipation and drugs such as 
dopamine agonists and anticholinergics.246 Levodopa itself may aggravate gastroparesis, 
in cases where it remains in the stomach for too long, allowing dopa-decarboxylase to 
convert it to dopamine.283 Non-pharmacological and pharmacological measures might 
ameliorate gastroparesis, some of them by promoting better levodopa absorption (Table 
5).246,284,285 
Constipation in Parkinson’s disease is mainly due to poor colonic contractions and 
functional outlet obstruction or both (Table 5).246,286 The functional outlet obstruction 
seems to result from a pelvic floor off period dystonia and usually improves with an 
increase in the dose of dopaminergic drugs or a local injection of botulinum toxin.246,287 
 
 
 
 
 
 
 
 
 
 
 
 
In Parkinson’s disease patients with urological symptoms, an accurate diagnosis is very 
important in order to prevent inappropriate urologic surgery,246 In patients complaining 
of detrusor overactivity symptoms, that is nocturia, urgency, frequency and urge 
incontinence, a urinary tract infection must be ruled out.260 Males may complain of 
bladder outflow obstruction symptomatology, such as hesitancy and poor flow, due to 
coexistent benign prostatic hyperplasia.246 Urgency may also be a manifestation of 
Table 5. Non-pharmacologic &  pharmacologic interventions for gastroparesis and  
constipation in   late-stage Parkinson`s disease 
Eat small regular meals; avoidance of proteins during the day.  
Take antiparkinsonian drugs during fasting 
Diet rich in insoluble fiber 
Avoidance of excessive gastric acidity   
Use domperidone. Attention to possible 
 risk of QT prolongation and ventricular tachyarrhythmia 
Try macrogol or tegaserod 
Management of  functional outlet obstruction:  
advise patients to evacuate during on or after taking a fast-acting agonist (ex: apomorphine);   
increase dopaminergic drugs dose; try local injection of  botulinum toxin; avoid use of laxatives 
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obstruction, because this can cause secondary detrusor overactivity.246, 260 Having 
excluded infection and obstruction, cystometry may be used to demonstrate detrusor 
overactivity, but pharmacotherapy can be started based solely on symptoms (Figure 1).260 
The postmicturition residual urine volume should then be measured by ultrasound, as the 
symptoms are poor predictors of the extent of incomplete emptying.260 In cases 
refractory to treatment or in those with a persistently large postmicturitional residual 
volume an evaluation by an urologist is advisable.260 
In candidates for prostatic surgery, a cystometry is mandatory in order to document 
outflow obstruction and a trial of anticholinergics is reasonable if frequency symptoms 
are prominent.246 One study with subcutaneous apomorphine showed a reduction in 
outflow obstruction symptoms, suggesting this could be used to test the reversibility of 
the obstruction before prostatic surgery.288 
Some Parkinson’s disease patients also develop a hypoactive detrusor, causing difficulty 
in initiating micturition, incomplete bladder emptying and urinary leakage.199 These 
patients could be started on α blockers, such as terazosin (1 – 5 mg at bedtime), 
doxazosin (1 – 8 mg at bedtime), alfuzosin (2.5 mg three times a day) or tamsulozin (0.4 – 
0.8 mg in the morning).199 However, these drugs may exacerbate orthostatic hypotension. 
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Figure 1. Management of detrusor overactivity 
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LS-PD in the context of ageing of world population 
Ageing of world population is expected to increase the prevalence of PD in future. The 
United Nations’ Report of 2013 estimates that the global share of older people (those ≥ 
60 years-old) will grow from 11.7% in 2013 to 21.1% in 2050.289 The number of older 
people will more than double from 814 million in 2013 to more than 2 billion in 2050, and 
this will affect both developed and less developed countries.289 Additionally, the older 
population is itself ageing, and the share of the “oldest old” (≥ 80 years-old) within the 
older population is projected to grow from 14% in 2013 to 19% in 2050, totalizing a 
projected figure of 392 million “oldest-old” people in 2050.289 Taking into consideration 
an age-adjusted prevalence of PD of 1.8% and that ageing is the strongest risk factor for 
developing PD, the prevalence of PD will increase substantially worldwide by 2050.29,290 
Likewise, an increase in life expectancy and better clinical management of PD is likely to 
increase the number of patients with a more prolonged disease course.92,291 As a longer 
duration of PD is associated with a higher frequency of motor symptoms and NMS 
resistant to L-dopa, the number of patients in LS-PD is also projected to increase 
substantially in the future.291 
This increase in the frequency of LS-PD will carry a higher burden of disease for patients, 
caregivers, and the healthcare and social security systems.291 Regarding the burden of 
patients, this is mostly driven from disability due to L-dopa resistant symptoms, for which 
we lack efficacious therapeutic interventions in the majority of the cases.41,56,57,154 
Similarly, caregivers’ burden correlates with disease progression and weekly hours of 
caregiving.141,143,144 Its major determinants are the symptoms that dominate LS-PD, 
behavioural and cognitive dysfunction, postural instability and falls.141,143,144 High burden 
of patients and caregivers impacts tremendously on society, at the level of the healthcare 
and social security systems, and having economic costs.291-293 Briefly, this is reflected in 
loss of employment and productivity, increase in outpatient and inpatient care, 
prescription costs and frequency of institutionalization.291-293 In fact, neurological 
disorders constitute 6.3% of the global burden of disease according to a WHO report, 
pinpointing neurological disorders as one major threat to public health.294 Although much 
less than the global burden from stroke or Alzheimer’s disease, PD contributes 
significantly to the loss of disability-adjusted life years (DALYs), that is, the number of 
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years expected to be lived in full health.294 Despite lacking specific data, we may 
speculate that LS-PD contributes even more to loss of DALYs than less advanced stages of 
PD. At an individual healthcare level, doctors and allied health professionals treating PD 
will face more frequently patients in late-stage, for whom they lack knowledge on the 
symptoms that most impact on their disability and which need to be prioritized. Patients 
in this stage are at risk of institutionalization and healthcare professionals working in 
nursery homes, who are not necessarily neurologists, will care more frequently for these 
patients. A recent study in Netherlands found that PD patients in nursery homes were 
severely disabled but almost half were considered to be undertreated according to a 
movement disorders neurologist, probably due to lack of knowledge of the specific needs 
of these patients.295    
Overall, this asks for a rational allocation of effective health and social security resources 
that cover patients’ and caregivers’ needs, but for which planning is crucial the existence 
of evidence on the health needs of LS-PD patients. That data is only partly reported 
nowadays. We think we have made a contribution to this body of evidence by specifically 
studying this emerging group of PD patients. We have covered the clinical manifestations 
of LS-PD patients, measured their handicap and the factors most contributing to handicap 
and perceived health status (HS), identified the medication use and the interventions 
from allied health professionals that these patients are using, and the overall healthcare 
they get, and we explored the burden of the carers of these patients and how they are 
affected by their relatives’ disease and handicap. Finally, we reviewed the available 
treatment options for the management of NMS, which are a major burden for these 
patients. 
Clinical features and handicap of LS-PD patients and burden of their 
carers 
We found that LS-PD patients still attending movement disorders clinics have long disease 
duration and a relatively young onset of PD. This contrasts with the reports of Weerkamp 
et al295,296 and Makoutonina et al297 on severely disabled parkinsonian patients living in 
nursery homes who were older, had a mean age at disease onset of 68 years and a mean 
PD duration of 10-12.7 years. Several reasons might explain this difference: almost half 
the patients (73 PD Dutch patients mostly in HY stage 4 or 5) included in the Weerkamp et 
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al study295,296 were considered to be in off state during most of the day and undertreated 
(25% were taking < 400 mg of L-dopa daily), so that one may speculate that part of them 
would no more be classified as HY stage 4 or 5 once they got the right treatment; 
secondly, PD starting at older age is a risk factor for a more severe disease course, which 
could additionally explain why these patients were institutionalized after only 8-9 years of 
disease;298,299 finally, the diagnosis of the patients (49 Australians with parkinsonism) 
included in the Makoutonina et al study297 could not be confirmed by the authors, so that 
cases of atypical, vascular or drug-induced parkinsonism may have been included. In 
addition and similarly to Weerkamp et al study, the patients included by Makoutonina et 
al297 were also treated with very low doses of L-dopa (mean 390 mg). On the other hand, 
our results also contrast with the reports of the long-term outcome of PD patients 
submitted to DBS, who also have very long disease duration as did our patients.76-
78,88,89,300-302 After 8-11 years of DBS, PD duration was longer (18-26 years) but patients 
were younger (<70 years) and had a younger age at disease onset (39.6-49 years) than 
ours. Even though having a longer disease duration, DBS patients had a better motor 
(UPDRS motor score 23.4-35) and ADL score (UPDRS part II ADL score 17.8-20), a better 
speech score (UPDRS mean speech item score 1.9-2.7) and less dementia (22.7-46%), but 
worse rigidity (UPDRS mean rigidity item score 3.4-5), than our patients.76-78, 88,89,300-302  
Our LS-PD patients are severely disabled from motor and non-motor symptoms. They 
have a symmetric akinetic parkinsonism with negligible rigidity and postural tremor, 
associated with severe postural instability, freezing of gait and falls, and prominent 
dysarthria and dysphagia. Interestingly, this motor syndrome is distinctly different from 
the classical motor phenotype of PD. Motor fluctuations and dyskinesias are frequent but 
not disabling, possibly in accordance with patients’ perception that L-dopa is still effective 
in partially relieving motor symptoms including tremor, though not potent enough to put 
patients in a good on state. Neuropsychiatric and dysautonomic symptoms are universal 
in these patients, and NMS fluctuate with L-dopa in two-thirds of the cases. Dementia is 
not inexorable in late stages of PD, as only half were demented, and the risk of dementia 
is higher in akinetic patients compared to tremor-dominant PD, as it is well 
established.61,303-305 The partial loss of benefit from L-dopa may be apparent owing to the 
use of lower than needed doses of antiparkinsonian drugs due to the frequent occurrence 
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of neuropsychiatric symptoms, or because of disease progression with increasing non-
dopaminergic involvement. Equally, the low doses of L-dopa found by Weerkamp et 
al295,296 may also be explained as a strategy to avoid side effects. We think there is a need 
to accurately assess the response of these patients to L-dopa. The disability of LS-PD 
patients may be also due to frequent co-morbidity and past medical diseases, although 
this was not apparent in our regression model. Despite severe disability and co-morbidity, 
they make low use of health resources such as allied health professionals, which is 
increasingly recommended.306,307 In contrast, almost all receive unpaid care, and the 
majority lives at their house. These unpaid caregivers spend much time with patients and 
report a high burden that is strongly determined by patients’ handicap.  
We found that LS-PD patients are highly handicapped, using the London Handicap Scale. 
The domain of handicapped most affected is Orientation, reflecting the high frequency of 
cognitive impairment in these patients. Accordingly, handicap is mostly driven by the 
presence of dementia, behavioural complaints and the severity of non-dopaminergic 
motor features. Interestingly, symptoms causing greatest impact on perceived HS of our 
patients (falls, gait unsteadiness, urinary dysfunction and sweats) do not fully overlap 
those associated with greater handicap, suggesting that handicap and perceived HS are 
similar but distinct measures of health states.101,308 In fact, perceived HS refers to 
perceived health in terms of physical and mental symptoms, social conditions or 
functions, and represents the impact of health on one’s ability to perform a variety of 
physical, emotional and social activities.101 Our study also found that patients with 
disabling L-dopa-induced motor complications (MC) have a moderate-to-severe handicap, 
although less than LS-PD patients. Moreover, the most affected domains of handicap in 
patients with MC are Physical Independence and Social Integration, whereas disability in 
ADL and dyskinesias are its major determinants. Overall, this data strongly suggest that 
LS-PD is distinctly different from advanced stage PD.    
We could measure handicap in LS-PD and advanced stage PD patients using the LHS, 
which was easily completed by patients and caregivers. In our study, we have explored for 
the first time handicap as a patient-centred outcome (PCO) measure in PD. The inclusion 
of PCO in PD research is increasingly important. Data on the health burden of PD from 
patients’ perspective are essential to understand the impact of disease in patients, to 
complement objective measures and to assess the effectiveness of therapeutic 
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interventions. The most commonly used PCO measures in PD research are the perceived 
HS, interference in ADL, the QoL and the health-related QoL (HRQoL).101,123,309,310 
Handicap is a rarely used PCO in PD, although widely used in other chronic neurological or 
non-neurological diseases, such as stroke sequelae.125,126,129,132,153,311-320 Although the 
WHO recently renamed the term handicap for participation restriction, the concept of 
handicap still holds true for clinical research.135-137 During the revision process led by the 
WHO, it was found a strong transcultural agreement on 6 domains of participation that 
can be potentially affected by health states,135-137 which, importantly, correspond to the 6 
usual dimensions of handicap. In contrast to handicap, QoL represents the internal 
experience of patients regarding the way they perceive and react to their health status 
and other non-medical aspects of their life, in the context of the culture and value 
systems in which the individual lives and in relation to her/his goals, expectations, 
standards and concerns.101,321,322 Although intimately related to the concept of (HR)QoL, 
handicap is more objective and more easily understandable to patients and caregivers, 
and allows the latter to answer the questionnaires in case patients are unable to do so 
owing to dementia or severe akinesia and dysarthria.125,129 Furthermore, comparison 
between populations of different origins is possible because there is good transcultural 
agreement on the construct of handicap.133,323 Overall, handicap might prove more 
understandable to patients and caregivers than (HR)QoL and a harder PCO measure of 
the impact of disease in the functioning of an individual. Our study provided for the first 
time data on the values of the LHS for advanced and late stage PD patients, which can be 
used as reference for future studies. The scale was easily completed by patients and 
caregivers of these 2 populations of PD, and it was brief to complete. In future, it would 
be important to assess the use of the LHS in earlier stages of PD and to evaluate how the 
scale behaves after an intervention, namely DBS.  
LS-PD is a distinct sub-group of advanced stage PD: proposal of a 
definition  
Our choice of the HY scale to define LS-PD patients resulted in the inclusion of very 
disabled patients due to motor and non-motor symptoms as was our intention, despite 
the limitations of the HY scale.82 Selecting our target population of LS-PD patients 
according to the presence of disabling MC, the most widely accepted definition for 
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advanced stage of PD, would have left out from the sample the most disabled PD patients 
and, additionally, would not capture very disabled patients who do not manifest MC at 
all. Paradoxically, the very disabled LS-PD patients that we included in the study are 
nowadays classified under the generic umbrella of advanced stage PD, although their 
phenotype vary considerably from the classic definition of patients in advanced stage. 
Indeed, the clinical features of patients with disabling MC selected to DBS that we report 
in Chapter 3 are very different from our LS-PD population. We think there is now enough 
data to conclude that LS-PD is a distinct sub-group of advanced stage PD. Besides, the 
emergence in future of LS-PD as a frequent and very disabling phenotype in the 
progression of PD will probably determine a change in the way we conceive today the 
natural history of PD.   
We propose the term late-stage to describe patients who are highly dependent on others 
in ADL, owing to L-dopa-resistant motor symptoms or NMS, at the best of L-dopa effect. 
Even though we have initially chosen the HY scale to define late-stage patients, we now 
propose to use the S&E scale95 to define late-stage patients, based on our results. The 
usage of the HY scale implies defining late-stage anchored in motor disability. Instead, the 
S&E scale is a tool developed to measure PD patients’ perceived functional 
independence.95 In our study, the mean S&E score of LS-PD patients was 30% in on and 
23% in off state, respectively. We think that a higher cut-off score would still allow to 
include very disabled patients due to motor or non-motor symptoms resistant to L-dopa. 
As a result, our proposed operational definition of late-stage PD is a score on the S&E 
scale of less than 50% during on period. A score of 50% corresponds with the patient 
requiring help with half of the chores and experiencing difficulty with all activities, while a 
score of 40% implies the patient being highly dependent on carers, able to assist with all 
chores, but unable to complete most tasks alone. Finally, albeit we think that the S&E 
scale and a 50% threshold are suitable to define LS-PD, discussion and further validation is 
still required. 
Treatment of NMS in LS-PD 
Since LS-PD patients are mostly disabled from axial motor and non-motor symptoms, the 
treatment of these symptoms is of paramount importance. In this regard, we reviewed 
the evidence on the pharmacological and non-pharmacological interventions to treat 
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these symptoms, using the principles of evidence-based medicine. Target symptoms to 
review were those responsible for most disability of PD patients in the later stages of 
disease and more specific of these later stages, based on the results from the Sydney 
cohort and our own study.56,57 This justifies why depression and anxiety were not 
reviewed: although frequent and disabling in later stages of PD, they are also very 
frequent in earlier stages of disease. At the time of the review, we considered “falls” a 
NMS which is something we would not do nowadays, as is manifest in this manuscript and 
other recent publications from our group.324-325 In fact, we had recently the opportunity 
to work in a systematic review of the treatment for the motor and non-motor symptoms 
of PD in which “falls” were classified among the motor symptoms of PD.41,154   
For the review, we selected controlled clinical trials (CCT) addressing the chosen target 
symptoms of LS-PD. However, these CCT enrolled PD patients who did not necessarily 
satisfied criteria for late-stage and we explicitly did not restrict our review to CCT 
recruiting late-stage patients only. This implies that the results of the review apply to PD 
patients in general but we do not know the effectiveness and safety of the covered 
interventions specifically in LS-PD patients. 
For many symptoms we did not find any CCT, and in other cases the quality of the trials is 
poor, indicating that there are unmet needs in the treatment of the symptoms affecting 
this population of PD patients. Furthermore, few trials included patients in late-stage and 
in many that information is not available in the report. As expected, the therapeutic 
interventions did not include L-dopa, suggesting that mostly these NMS are mediated 
through non-dopaminergic pathways.      
Implications for clinical practice 
This new and emerging phenotype of LS-PD is distinct from the classical advanced stage 
patients, and our study made possible to detail its clinical features, medication use, 
determinants of handicap and available treatment options tested in CCT. LSDP patients 
and their caregivers will be a clinical challenge to treating physicians, whether 
neurologists, geriatricians or general practioners, and allied health professionals. This 
health personnel and patients´ caregivers will require specialist training to manage these 
patients. 
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Health professionals should be proactive in asking patients and caregivers about the 
symptoms which we now know most contribute to their handicap. Clinical assessment 
and therapeutic interventions should focus on such problems as falls and postural 
instability, urinary dysfunction, freezing, bradykinesia, dysarthria and choking, dementia, 
psychosis, excessive daytime sleepiness, apathy, depression and anxiety. However, 
rigorous ascertainment of some of these symptoms is particularly difficult in this 
population, owing to severe dysarthria, dementia and daytime somnolence. Treatment 
for MC should be less of a priority. 
Adequate management of this population of patients and their caregivers is complex and 
requires a multidisciplinary approach. Both health and social interventions will probably 
be necessary to improve the health state and reduce the handicap of these individuals, 
and these interventions must be cost-effective. Therapeutic interventions should be 
pharmacological and non-pharmacological. Unfortunately, effective treatments are 
lacking for many of these L-dopa-resistant symptoms, as shown by our study and more 
recent work.41,154,326 Pharmacological management is further complicated by a high 
frequency of adverse effects in these patients, and so management strategies should aim 
for regimen simplification. 
Implications for research 
Basic research regarding the pathogenesis and neuropathology of L-dopa-unresponsive 
symptoms is fundamental to achieve new understanding that will allow research of 
innovative molecules to treat these disabling symptoms.327 This research should focus on 
non-dopaminergic pathways and extra-nigral structures.1,2,191,328  
There is plenty to do regarding clinical research in LS-PD. Longitudinal data on the motor 
and non-motor progression of LS-PD patients is valuable in order to estimate, even 
though indirectly, the rate of neurodegeneration at this late stage which is known to 
differ from that in earlier stages.168 LS-PD is a good clinical model to identify the disability 
milestones that cause most disability and predict mortality, highlighting the symptoms 
that should be targeted for drug development at earlier stages of PD.105,188 Studies 
assessing the clinimetrics of scales for PD have, as a rule, included few late stage patients 
so it is lacking robust data on the behaviour of most scales in this population. In fact, 
many of the available scales may even not be adequate to assess these very advanced 
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patients, and adaptations of these scales or even new tools may be needed. Other 
research techniques such as qualitative research may be of value addressing the multiple 
problems of these patients and carers. Missing is still a precise evaluation of the response 
of the motor and non-motor symptoms of these patients to L-dopa, to disclose whether 
the reported loss of benefit from L-dopa is only apparent due to the use of low doses 
because of side effects or the consequence of widespread disease progression.295,296 
Finally, new CCT testing therapeutic interventions or management strategies in LS-PD are 
urgently needed.307,329       
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 ADL   Activities of daily living  
 BDI    The Beck Depression Inventory  
 CI   Confidence interval 
 COMT inhibitors  Catechol-O-methyl transferase inhibitors 
 CT   Computed tomography 
 DALYs    Disability-adjusted life years  
 DBS    Deep brain stimulation  
 (HR)QoL   Health-related Quality of life 
 HS    Health status  
 HY    Hoehn and Yahr  
 L-dopa    Levodopa  
 LEDD    Levodopa equivalent daily dose  
 LHS    London Handicap Scale  
 LS-PD    Late-stage PD  
 mAIMS    modified Abnormal Involuntary Movement Scale  
 MC    Motor complications  
 MDS-UPDRS   Movement Disorders Society- Unified Parkinson’s disease 
Rating Scale 
 MMSE    Mini Mental State Examination  
 MRI   Magnetic resonance imaging 
 NA   Not applicable or not available 
 NMS    Non-motor symptoms  
 PCO    Patient-centred outcome  
 PD   Parkinson`s disease  
 QoL    Quality of life  
 SD   Standard deviation 
 S&E    Schwab & England Scale  
 SN    Substantia nigra  
 SNpc    Substantia nigra pars compacta  
 UPDRS    Unified Parkinson`s Disease Rating Scale  
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 WHO    World Health Organization 
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